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Familial Combined Hyperlipidemia (FCH) with a population prevalence of 1 -2% in 
Caucasians is the most common dyslipidemia that can cause Coronary Artery Disease 
(CAD). FCH is a multi-factorial and polygenic lipid disorder characterized by elevated 
total cholesterol (TC) and/or total triglyceride (TG) levels. FCH probands must have at 
least one first-degree relative who has lipid phenotype IIB (elevated both TC and TG 
levels), or a lipid phenotype different from that of the proband. Previous papers have 
reported that single nucleotide polymorphisms (SNPs) in the apolipoprotein 
A1/C3/A4/A5 gene cluster (APOA1/C3/A4/A5), upstream transcription factor 1 (USFl) 
gene and a-Adducin gene are associated with FCH, CAD or elevated TG levels in 
Caucasians. These SNPs are also associated with CAD or elevated TG levels in Chinese. 
Some studies have shown that the SNPs in the lipoprotein lipase (LPL) gene and the 
peroxisome proliferators-activated receptor gamma (PPARy) gene have protected 
Caucasians and Chinese from CAD. In contrast to FCH patients, Combined 
Hyperlipidemia (CH) patients having lipid phenotype IIB only do not necessarily have 
first-degree relatives with elevated lipid levels. To my knowledge, no studies were found 
regarding the associations between these SNPs and FCH or CH in Chinese. Hence, this 
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study aims to investigate whether these SNPs are specifically associated with FCH or 
CH in Chinese. 
In this case-control study, 56 FCH cases, 115 CH cases and 176 normal controls, all 
genetically unrelated within groups and having an origin of southern China Han ancestry 
were recruited in the Prince of Wales Hospital, Hong Kong between 1995 and 2000. 
Among them, thirty-five subjects with the lipid phenotype IIB who had first-degree 
relatives with elevated lipid levels were defined as both FCH and CH cases. All 
participants were asked to do the Genetic Hyperlipidemia Survey questionnaires. Their 
height, weight, lipid profiles, serum glucose level and blood pressure were measured. 
Their DNA samples were extracted by the traditional phenol-chloroform method or the 
commercial DNA extraction kit (Roche). Twenty-five SNPs in the APOA1/C3/A4/A5 
gene cluster, USFl, LPL, PPARy or the a-Adducin gene selected from the previous 
papers or the Hapinap were genotyped by the MassARRAY System (Sequenom) in the 
Hong Kong University Genome Research Centre. Finally, the genotyping results were 
analyzed by the programs of SPSS 13.0 (SPSS Inc.) and Haploview (Daly Lab.). 
The main findings of this study were as follows: 
1. FCH in Chinese was significantly associated with one SNP (rs4520) in AP0C3 {P 
<0.05), two SNPs (rs6589567, rs6589568) in APOA4-A5 (户<0.05) and four SNPs 
(rs65]82I, rs662799, rs2075291, rs2266788) in AP0A5 (户<0.001). The odds 
ratios of developing FCH in minor allele homozygotes of rs65182], rs662799, and 
rs6589568 compared with their major allele homozygotes were 24.4, 24.6 and 3.9 
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respectively adjusted for age, gender and BMI. The pooled adjusted odds ratios of 
developing FCH in the minor allele carriers of rs2075291, rs2266788 and 
rs6589567 compared with the major allele homozygotes were 4.4, 6.2 and 2.2 
respectively. Two SNPs (rs2075291 and rs22667881 in AP0A5 were associated 
with lower HDL-C levels among different genotypes in FCH cases and controls 
respectively adjusted for age, gender and BMI (P<0.05). One haplotype in AP0C3, 
one novel haplotype in APOA4-A5 and two haplotypes in AP0A5 were also 
significantly associated with FCH in Chinese (尸<0.05). 
2. CH in Chinese was significantly associated with three SNPs (rs4520, rs5128, 
rs2854116) in AP0C3 (P<0.05), three SNPs (rs6589567. rs6589568, rs 1729410) 
in APOA4-A5 (P<0.05) and three SNPs (rs651821. rs662799, rs2266788) in 
AP0A5 (?<0.001). In AP0A5, the odds ratios of developing CH in minor allele 
homozygotes of rs651821, rs662799, and rs2266788 compared with the major 
allele homozygotes were 17.0, 16.8 and 5.3 respectively adjusted for age, gender 
and BMI (? <0.001). In AP0C3 and APOA4-A5, the adjusted odds ratios of 
developing CH in minor allele homozygotes of rs5128, rs2854116, rs 1729410, 
rs6589567 and rs6589568 compared with the major allele homozygotes were 3.8, 
3.0, 0.2, 3.5, and 3.5 respectively (尸<0.05). Two SNPs (rs65182K rs662799) in 
AP0A5 were associated with higher TG levels among different genotypes in CH 
cases adjusted for age, gender and BMI (?<0.05). Two haplotypes in AP0C3, one 
novel haplotype in APOA4-A5 and two haplotypes in AP0A5 were also 
significantly associated with CH in Chinese (P <0.05). 
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3. No SNPs in the USFl, LPL, PPARy or the a-Adducin gene were significantly 
associated with FCH or CH in Chinese. 
4. Two SNPs in AP0A4 (rs675, G360H) and one SNP (i-s6656547) in USFl were 







脂代謝異常，特徴是升高的總膽固醇水平 (TC)或總甘油三脂水平 (TG)�FCH的先 
證者必須有至少一個第一級的近親屬具有 I IB的脂代謝諫型（升高的總膽固醇水 
平T C以及總甘油三脂水平T G )，或者是與先證者不同的脂代謝諫型。先前的報 








在本病例對照研究中，收集5 6個F C H病人，1 1 5個C H病人和� 7 6個正常 
對照。這些病例内部無遺傳聯繁，屬于華南漢族，收集于1995年到2000年的香 




品採用傳統的酚一氯彷抽取方法或商業化的D N A提取試劑盒（R o c h e )進行提 
取。有 25 個位于 APOAl/C3/A4/A5,USn，LPL,PPARY 以及 a-Adducin 的 SNP 位點 
通過已发表的文獻或Hapmap選出，並使用MassARRAY系統在香港大學基因組 
研究中心進行分型。結果使用SPSS 13.0 (SPSSInc)和Haploview (Daly L a b )進 
行分析。 
主要的研究发現為： 
1. FCH 在華人中與 I 個 AP0C3 的 SNP 位點 rs4520 (P < 0.05)，2 個 APOA4-A5 的 
SNP 位點 rs6589567, rs6589568 (P < 0.05)和 4 個 AP0A5 的 SNP 位點 rs65�821， 
rs662799, rs2075291，rs2266788 (P < 0.001)顯著相關。對于 rs651821，rs662799和 
rs658956的低豐度同源位點純閤子與高豐度的同源位點純閤子比較，发生FCH的 
優勢率比為分別為24.4, 24 .6和3.9 (經調整過年齢，性別和BM1后 )� r s2075291, 
r s2266788和 r s6589567的低豐度同源位點純閤子與高豐度的同源位點純閤子比 
較，調整過的发生FCH的優勢率比分別為4.4, 6 . 2 和 2 . 2 � 2 個 A P 0 A 5 的 S N P 位 
點 r s2075291和 r s2266788經調整過年齢，性別和BMI后，在不同的基因型中发 
現與低HDL-C水平相關(P < 0 . 0 5 ) � A P 0 C 3的1個基因型別，A P O A 4 - A 5的1個 
新型基因型別和AP0A5的2個基因型別在華人中與FCH顯著相關（P < 0.05)� 
2. CH 在華人中與 3 個 AP0C3 的 SNP 位點 rs4520, rs5128, rs2854] 16 (P < 0.05)，3 
個 APOA4-A5 的 SNP 位點丨.s6589567, rs6589568 rs 1729410 (P < 0.05)和 3 個 
AP0A5 的 SNP 位點 rs651821, rs662799, rs2266788 (P < 0 .001 )顯著相關。在 
AP0A5中，rs651821, rs662799和rs2266788的低豐度同源位點純閤子與高豐度的 
同源位點純闇子比較，发生CH的優勢率比為分別為17.0, 16.8和5.3 (經調整過年 
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齢，性別和 BMI 后）（P < 0 . 0 0 1 ) �在 AP0C3 和 APOA4-A5 中，rs5]28, rs2854]]6, 
i-s 1729410, rs6589567,和rs6589568的低豐度同源位點純閤子與高豐度的同源位點 
純閤子比較，調整過的发生C H的優勢率比分別為3 . 8，3 . 0 , 0.2, 3 . 5和 3 . 5 (P < 
0 . 0 5 ) � 2個A P 0 A 5的S N P位點 r s 6 5 � 8 2 1和 r s 6 6 2 7 9 9經調整過年齢，性別和B M I 
后，在不同的基因型中发現與高TG水平相關（P < 0 . 0 5 ) � A P 0 C 3 的 2 個基因型 
別，A P O A 4 - A 5的1個新型基因型別和A P 0 A 5的2個基因型別在華人中與C H顯 
著相關（P<0.05)� 
3 .在U S F 1 , LPL, PPARy以及a-Adckic in中沒有发現SNP位點與華人中的FCH或 
CH顯著相關。 
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Chapter one Introduction 
1.1 Lipids, lipoproteins and lipid metabolism 
Lipids are oily waxy substances of animals or plants that can serve as structural 
elements of cell membranes, as energy storage, and as insulators (Tietz 1982). In 
physiologic fluids and in tissues, most lipid molecules combine with proteins to form 
lipid-protein complexes or lipoproteins that can promote solubility of the lipids in an 
aqueous medium (Tietz 1982). Major clinical interest has focused on the association 
of blood lipids and lipoproteins with atherosclerosis related diseases such as Familial 
Combined Hyperlipidemia (FCH) and Coronary Artery Disease (CAD). 
Atherosclerosis is the process of lipid deposition on the artery walls that causes their 
thickening and narrowing of arteries. 
1.1.1 Cholesterol 
Cholesterol, a white fatty substance with a chemical formula of C27H45OH, 
(Figure 1) is an important part of the human cell membranes (Tietz 1982). Dietary 
intake and liver production are two major sources of cholesterol. In tissues such as 
liver, intestines and adrenal glands, cholesterol is primarily synthesized from 
acetylCoA through the HMG-CoA reductase pathway. 
1 








Triglycerides are the simple esters of fatty acids and glycerol (Figure 2). They 
constitute most of the adipose tissue mass. They also play an important role in 
metabolism as energy sources by being hydrolyzed and converted to fatty acids 
through the action of lipases (Tietz 1982). 
Figure 2. Triglyceride structure 
— J — R . 
o 
CH ——O—C — R•丨 
O 
CH2 ——O—C — R'" 
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1.1.3 Lipoproteins and their metabolic pathways 
There are four main types of lipoproteins i.e. chylomicrons (Cm), very low 
density lipoprotein (VLDL), low density lipoprotein (LDL) and high density 
lipoprotein (HDL) involved in the metabolic pathways that can affect serum 
cholesterol and triglyceride levels in human beings (FigiireS) (Shoulders, Jones et al. 
2004). While the chylomicrons and VLDL are primarily triglyceride transport 
vehicles, the major lipid components of the LDL and HDL are cholesterol (Tietz 
1982). After a meal, cholesterol and triglycerides are absorbed by the intestines, and 
then transported to the liver in chylomicrons and chylomicron remnants (Shoulders, 
Jones et al. 2004). In the liver, the lipids mainly triglycerides are incorporated into 
lipoprotein particles and released back into the bloodstream as VLDL that transports 
triglycerides to other organs (Tietz 1982). VLDL is converted to the intermediate 
density lipoprotein (IDL) and LDL by losing triglycerides through the action of 
lipoprotein lipase. When total triglyceride (TG) levels are high, IDL particles are 
converted to small and dense LDL particles. LDL carrying cholesterol to other body 
cells is called "bad cholesterol" because it is associated with atherosclerosis and 
increased risk for CAD. HDL carries cholesterol from the body tissues to the liver. In 
HDL particles, cholesterol is converted into cholesteryl ester through the action of 
lecithin cholesterol acyltransferase (LCAT). As high concentrations of HDL can 
n 
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protect people against CAD, it is seen as "good cholesterol" (Tietz 1982). In the liver, 
the returned cholesterol is converted to bile salts in bile that serves to emulsify 
ingested fats and thereby promote digestion. 
Figure 3. Cholesterol and triglyceride metabolic pathways. The figure is adapted 
from the study of Shoulders et al (Shoulders, Jones et al. 2004). 
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1.2 Familial Combined Hyperlipidemia and Combined Hyperlipidemia 
FCH is the most common genetic dyslipidemia with a prevalence of 1-2 % in 
Caucasians (Goldstein, Schrott et al. 1973; Grundy，Chait et al. 1987). FCH patients 
have elevated total cholesterol (TC) and/or total triglyceride (TG) levels, elevated 
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apolipoprotein B (apoB) levels, and increased numbers of small-dense LDL particles 
(Hokanson, Krauss et al. 1995; Ayyobi, McGladdery et al. 2003). They may also 
have elevated LDL, VLDL levels and reduced HDL levels (Gagnon, Jarvik et al. 
2003; Pajukanta, Allayee et al. 2003). Traditionally, the diagnosis of FCH is based on 
three different lipid phenotypes: elevated TC levels (phenotype IIA), elevated TC 
and TG levels (phenotype IIB, combined hyperlipidemia) and elevated TG levels 
(phenotype IV). FCH probands must have at least one first-degree relative (blood 
relative) who has lipid phenotype IIB, or a lipid phenotype different from that of the 
probands. The Finnish, British and US FCH studies required FCH probands' TC 
and/or TG levels must be above or equivalent to percentile adjusted for age and 
gender (Pajukanta, Nuotio et al. 1998; Hopkins, Heiss et al. 2003; 
Eichenbaum-Voline, Olivier et al. 2004). Another Dutch study used absolute TC and 
TG levels (TC>6.5mM, TG>2.3mM) with apoB levels above 75''' percentile as cutoff 
points (Aouizerat, Allayee et al. 1999). A recent study by Veerkamp et al has shown 
that FCH can be best predicted by the elevated TC and/or TG levels combining with 
the elevated absolute apoB levels adjusted for age and gender (Veerkamp, de Graaf et 
al. 2004). Patients with Type 1 and Type 2 diabetes, renal, liver or thyroid disorders 
must be excluded because these diseases can also cause elevated TC and/or TG 
levels. 
5 
Metabolic abnormalities including dyslipidemia, obesity, hyperglycemia, insulin 
resistance and hypertension are the phenotypic overlaps among FCH, the metabolic 
syndrome (MES) and diabetes. According to the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP III) guidelines, MES patients must have at 
least three of five risk factors including hyperglycemia, hypertension, 
hypertriglyceridemia, low HDL-C and central obesity (Expert Panel on Detection 
Evaluation and Treatment of High Blood Cholesterol in Adults 2001). Unlike the 
diagnostic criteria of MES, FCH requires that multiple members within a family have 
elevated TC and / or TG levels. In FCH studies, the diabetes patients with elevated 
plasma glucose levels must be excluded. 
It has been hypothesized that insulin resistance and abdominal obesity may be the 
key factors linking these phenotypic overlaps (Reaven 1992; Chaour, Theroux et al. 
1997; Ascaso，Real et al. 1999; Keiilen, Voors-Pette et al. 2001). Insulin resistance is 
defined as a diminution of the biological response to a given concentration of insulin 
(Ascaso, Real et al. 1999). Several studies have shown that FCH subjects have higher 
degree of insulin resistance relative to control subjects (Hunt, Wu et al. 1989; 
Castro-Cabezas, de Bruin et al. 1993; Ascaso, Merchante et al. 1998). Arner et al 
have suggested that insulin resistance increases the flux of free fatty acid to the liver 
causing higher VLDL secretion, higher plasma levels of small and dense LDL 
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particles and lower plasma levels of HDL-C (Arner 1997; Sniderman, Cianflone et al. 
1998). The increased free fatty acid levels can also induce higher plasma glucose 
levels. Some other studies have identified waist circumference, a measure of 
abdominal obesity and visceral fat as the link between FCH and hypertension (Austin, 
Horowitz et al. 1992; Ascaso, Real et al. 1999). 
In the Hong Kong Family Diabetes Study, Ng and colleagues used autosomal 
genome scans to map loci for MES and related traits (Ng, So et al. 2004). They found 
a susceptibility locus on chromosome Iq21-q25 involved in MES (LOD = 4.5), waist 
circumference (LOD = 3.71) and DBP (LOD = 1.24) in Hong Kong Chinese (Ng, So 
et al. 2004). Some other studies have also indicated that this region is associated with 
FCH or dyslipidemia (Pajukanta，Nuotio et al. 1998; Coon, Myers et al. 2000; Pei， 
Baron et al. 2000), MES (Langefeld, Wagenknecht et al. 2004), obesity (Weyer, 
Wolford et al. 2001) and type 2 diabetes (McCarthy 2003; Ng, So et al. 2004). 
FCH patients have greater risk for CAD that is the leading cause of death in 
developed countries (Austin, McKiiight et al. 2000; Voors-Pette and de Bruin 2001; 
Hopkins, Heiss et al. 2003). The study by Voors-Pette et al showed that the odds ratio 
(OR) for CAD was 5.3 in male FCH relatives (95% confidence interval, 1.65-17.08, 
？=0.005) and 5.1 in all FCH relatives (95% CI, 1.87-13.88, P=0.001) respectively 
compared with spouse controls (Voors-Pette and de Bruin 2001). Another 20-year 
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prospective study by Austin and colleagues found that the odds ratio for CAD 
mortality was 1.7 (95% CI, 1.1-2.7,户=0.02) compared with spouse controls after 
adjustment for covariates (Austin, McKnight et al. 2000). Hopkins et al conducted a 
population-based case-control study to determine the CAD risk in FCH and Familial 
Hypertriglyceridemia (FHTG) (Hopkins, Heiss et al. 2003). They found that both 
FCH and FHTG were associated with an odds ratio of 2.0 for CAD (户=0.003 and 
0.002, respectively) (Hopkins, Heiss et al. 2003). They also suggested that the CAD 
risk in FCH and FHTG was strongly related to the major components of the 
metabolic syndromes such as diabetes and hypertension (Hopkins, Heiss et al. 2003). 
Different from FCH patients, CH patients are classified as lipid phenotype IIB 
only (elevated TC and TG levels). Moreover, they do not necessarily have a 
first-degree relative with elevated TC and/or TG levels. FCH patients who have lipid 
phenotype IIB are also defined as CH patients simultaneously, so there is an overlap 
between two groups. Patients with diabetes, renal, liver and thyroid disorders must be 
excluded. No study was found to provide direct evidences of the association between 
CH and the greater risk for CAD. It is reasonable to postulate that CH patients should 
have greater risk for CAD because of the similar disease phenotypes (elevated TC 
and/or TG levels) of FCH and CH. 
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1.3 Single nucleotide polymorphisms 
Single nucleotide polymorphisms (SNPs) are single base pairs in genomic 
deoxyribonucleic acid (DNA) at which different alleles exist (Brookes 1999). Their 
minor allele frequency should be 1 % or greater. As human beings have rare tri-allelic 
and tetra-allelic SNPs, they can simply be referred to bi-allelic markers (Brookes 
1999). Among four basic SNP types including C/T，C/A, C/G and T/A, two third of 
them involve C/T conversions. The International SNP Map Working Group has 
identified 1.42 million SNPs throughout the human genome with an average density 
of 1 SNP every 1900 base pairs (The International SNP Map Working Group 2001). 
1.3.1 SNP genotyping methods 
Hybridization, primer extension and cleavage methods are three traditional SNP 
genotyping methods that use different detection technologies such as fluorescent 
polarization, luminometric detection of pyrophosphate release (pyrosequencing) and 
mass spectrometry (Nowotny, Kwon et al. 2001). Recently, biotechnology companies 
have developed different high-throughput systems for SNP detection and genotyping. 
They include the mass spectroscopy-based MassARRAY system (Sequenom), the 
fluorescent microaiTay-based systems (Affymetrix) and the fluorescent bead-based 
technologies (Luminex, Illumina, Q-dot), etc (Gray, Campbell et al. 2000). 
Compared with the traditional methods, these advanced systems can genotype SNPs 
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with higher speed, lower costs and greater efficiency. 
1.3.2 Associations of SNPs with genetic diseases 
SNPs can be associated with genetic diseases by affecting the function of the 
genes in which they are located (Nowotny, Kwon et al. 2001). They can cause a 
synonymous change (no amino acid change) or a non-synonymous change (an amino 
acid substitution) in the coding or non-coding sequences of a gene. A synonymous 
change may alter exon-intron messenger ribose nucleic acid (mRNA) splicing, 
meanwhile a non-synonymous change can cause an amino acid substitution 
(Nowotny, Kwon et al. 2001). Both changes can directly modify the relevant proteins 
involved in the disease processes. SNPs in the regulatory region of a gene can change 
the level of gene expression or the stability of the mRNA. A SNP can also be in 
linkage disequilibrium (LD) or known as allelic association with another "true" 
functional SNP of diseases (Nowotny, Kwon et al. 2001). 
1.4 Genetic analysis of FCH and CH 
FCH and CH are multi-factorial and polygenic lipid disorders resulting from 
various genetic and environmental risk factors. To dissect the complex diseases 
genetically, the approaches of genome scans and SNP based candidate gene analysis 
can be used. 
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1.4.1 FCH genome scans 
Genome-wide screens are used to identify the potential chromosomal regions that 
contain the candidate genes associated with FCH. In Finnish families, there was a 
linkage of FCH to chromosome Iq 21-23 with a log of odds (LOD) score of 5.93 
(Pajukanta, Nuotio et al. 1998). Pei et al conducted a combined German-Chinese 
study that also confirmed linkage of FCH to region lq21-23 (LOD 2.6) (Pei, Baron 
et al. 2000). Coon et al has also reported a positive linkage of FCH to chromosome 
Iq markers with the highest LOD score of 5.93 occurring at a location between 
D1S104 and D1S1677 (P105R39) (Coon, Myers et al. 2000). A Dutch study showed 
FCH linkage to chromosome l i p with a LOD score of 2.6 (Aouizerat, Allayee et al. 
1999). 
1.4.2 SNP based candidate gene analysis 
As each multiple gene variant only contributes a small effect to the polygenic 
FCH and CH, the linkage analysis using large pedigrees may have limited power to 
detect genes with minor contributions (Nowotny, Kwon et al. 2001). SNP based 
candidate gene analysis using unrelated cases and controls should have a better 
chance to detect the small effects of the multiple gene variants (Nowotny, Kwon et al. 
2001). The analysis selects candidate genes according to the genome scans results 
and the basis of biological functions. SNPs on the candidate genes are genotyped to 
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test for association with FCH or CH. If the allele of a SNP has a significantly higher 
frequency in the diseased group (cases) compared with the non-diseased group 
(controls), the SNP has a disease allele that is significantly associated with FCH or 
CH. Selection of appropriate patients and controls is critical for the validity of the 
analysis. As new high-throughput systems such as the MassARRAY system 
(Sequenom) can genotype the SNPs on the candidate genes efficiently and cost 
effectively, SNP based candidate gene analysis is a feasible approach to study FCH 
and CH. 
1.5 Candidate genes and SNPs associated with FCH and CH 
1.5.1 Apolipoprotein A1/C3/A4/A5 gene cluster 
Four major apolipoproteins including apolipoprotein Al (apoAl), apolipoprotein 
C3 (apoC3), apolipoprotein A4 (apoA4) and apolipoprotein A5 (apoA5) regulate and 
control the plasma lipoprotein metabolism (Table 1). The Apolipoprotein A1/C3/A4 
gene cluster in the chromosome llq23 region which spans 17kb was first 
characterized by Karathanasis in 1985 (Karathanasis 1985). Recently, apolipoprotein 
A5 gene (AP0A5) was identified approximately 30kb upstream of apolipoprotein A4 
gene (AP0A4) (Figure 4a-e) (Pemiacchio, Olivier et al. 2001). SNPs on the 
apolipoprotein A1/C3/A4/A5 gene cluster (APOA1/C3/A4/A5) have been shown by 
various studies to associate with FCH, CAD and elevated lipid levels, so the gene 
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cluster should be a good candidate for investigating FCH and CH in Chinese. 
Table 1. Properties of apolipoproteins and their roles in the lipoprotein metabolism. 
The data is adopted from the studies of Mahley et al (Mahley，Imierarity et al. 1984) 
and van Dijik et al (van Dijk, Rensen et al. 2004). 
Plasma Molecular Molecular 
Apolipo Sites of Roles in the lipoprotein 
concentration size weight 
-proteins synthesis metabolism 
( m g / d l ) (amino acids) ( D a ) 
Major protein constitutent of 
Liver and 
apoAl 100-150 243 28,100 HDL, an obligatory cofactor for 
intestine 
LCAT 
Second most abundant protein 
apoA2 Liver 30-40 77 17,400 component of HDL, its function 
is unknown 
Modulate the uptake of 
triglyceride-rich remnants by 
Liver and 
apoC3 . 12 79 8,750 hepatic receptors, activate LCAT, 
intestine 
a non-competitive inhibitor of 
LPL activity 
. May play a role in lipid 
Ljver and 
apoA4 . 15 376 46,000 absorption, may be a cofactor for 
intestine 
LCAT 
Mainly present on HDL, may 
trigger TG lowering activity by 
apoA5 Liver 0.016-0.020 343 39,000 retarding triglyceride-rich particle 
assembly and/or increasing LPL 
activity 
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Figure 4a-e. APOA1/C3A4/A5 gene cluster, (a) genomic regions resequenced, (b) 
exon structure and direction of transcription of each gene, (c) previously identified 
regulatory regions, (d) repeat sequence features, (e) locations of the 124 polymorphic 
variants identified. The figure is adapted from the study of Fullerton et al (Fullerton, 
Buchanan et al. 2004). The scale measures the length of the gene sequences in 
kilobases (kb). 
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1.5.1.1 Apolipoprotein Al gene 
>> 
Apolipoprotein Al , a major protein found in HDL, is the obligatory cofactor of 
the enzyme LCAT that regulates the reverse cholesterol transport from peripheral 
tissues to the liver (Groenendijk, Cantor et al. 2001). The transgenic mice 
overexpressing the human apolipoprotein Al gene (APOAl) were protected from the 
development of diet-induced atherosclerosis (Rubin, Krauss et al. 1991), meanwhile 
mice lacking APOAl were found to have progressive atherosclerotic lesions (Paigen, 
Ishida et al. 1990). 
APOAl Milano is the mutant.form of APOAl that is formed as a result of 
arginine 173 to cysteine substitution (Franceschini, Siitori et al. 1980). Ameli et al 
have found that recombinant APOAl could reduce experimental atherosclerosis in 
cholesterol-fed rabbits (Ameli, Hultgardh-Nilsson et al. 1994). Li et al have 
suggested that administration of recombinant APOAl Milano could inhibit 
platelet-dependent thrombus formation in a rat model (Li, Weng et al. 1999). It has 
been postulated that APOAl Milano protects against vascular disease by removing 
cholesterol from tissues (Franceschini, Vecchio et al. 1985; Ameli, 
Hultgardh-Nilsson et al. 1994). The structural modification of the APOAl Milano 
may contribute to the accelerated catabolism of the lipid-protein complexes and 
increased efficiency for uptake of tissue lipids(Roma, Gregg et al. 1993). 
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For the SNP with the reference SNP ID 5070 (rs5070) (APOAl 317 C>T) on 
APOAl, the Chi-square tests have shown that its minor allele frequencies were 
significantly higher in Caucasian FCH probands (n=30) than in their spouses (n=218) 
(47% vs 25%,户<0.001) (Groenendijk, Cantor et al. 2001). Its minor allele 
homozygotes were associated with elevated TG levels (Groenendijk, Cantor et al. 
2001). 
1.5.1.2 Apolipoprotein C3 gene 
Apolipoprotein C3 is a 79-amino-acid glycoprotein found on VLDL, Cm and 
HDL particles. It is also an exchangeable component of triglyceride-rich lipoproteins 
and HDL (Groenendijk，Cantor et al. 2001). It has been suggested that apoC3 may 
modulate the uptake of triglyceride-rich remnants by hepatic receptors (Shelburne， 
Hanks et al. 1980; Windier, Chao et al. 1980), and activate LCAT (Jonas, Sweeny et 
al. 1984). As a non-competitive inhibitor of lipoprotein lipase mediated triglyceride 
hydrolysis, it reduces the capacity to hydrolyze triglyceride-rich lipoproteins (Wang, 
McConathy et al. 1985; Ginsberg, Le et al. 1986). Overexpression of human 
apolipoprotein C3 gene (AP0C3) in transgenic mice was reported to cause severe 
FHTG (Ito, Azrolan et al. 1990), whereas AP0C3 deficiency decreased TG levels in 
knockout mice (Maeda, Li et al. 1994). 
The minor allele of rs4520 (AP0C3 l lOOOT) was found to have higher 
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genotype and allele frequencies in Caucasian FCH probands (n=30) as compared 
with those in their spouses (n=218) (P<0.002) (Groenendijk, Cantor et al. 2001). Its 
minor allele homozygotes were also associated with elevated TG levels (Groenendijk, 
Cantor et al. 2001). It has been shown that minor allele frequency of rs5128 (AP0C3 
3238 G � C , SstI) was significant higher in Caucasian FCH probands (n=78) than in 
their spouses (n=104) (P=0.03) (Mar, Pajukanta et al. 2004). The frequency of the 
haplotype carrying the minor alleles of rs452Q and rs5128 was significantly higher in 
Caucasian FCH probands as compared with spouses (户<0.001) (Groenendijk, Cantor 
et al. 2001). The minor allele of rs2854116 (AP0C3 -455 T � C ) was significantly 
associated with an increased risk of CAD (OR=2.18 after adjustment) and increased 
TG levels in Caucasian CAD patients (n=549) as compared with CAD-free controls 
(n=251) (Olivieri，Stranieri et al. 2002). 
1.5.1.3 Apolipoprotein A4 gene 
In fasting plasma, apoA4 is mainly found in HDL particles (Green, Glickman et 
al. 1980). It plays a role in lipid absorption because patients with its deficiency had 
the problem of fatty acid malabsorption (Ordovas, Cassidy et al. 1989). It was also 
found to promote cholesterol efflux from peripheral tissues (Steinmetz, Barbaras et al. 
1990; Fournier, Atger et al. 2000) or to be a cofactor for LCAT (Delamatre, 
HofFmeier et al. 1983; Steinmetz and Utermann 1985). 
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The minor allele of rs675 (AP0A4 347 A>T, Hinfl) was observed to have a 
significantly lower frequency in Caucasian FCH probands (n=78) as compared with 
spouses (111=104) (P=0.01), suggesting a protective role of the minor allele in the 
development of FCH (Mar, Pajukanta et al. 2004). Its minor allele carriers (n=133) 
had higher TC and TG levels as compared with those of non-carriers (n=242) in the 
control subjects of the European Atherosclerosis Research Study II (户<0.02 and 
户<0.003 respectively) (Fisher, Burke et al. 1999). APOA4G360H was found to lead 
to a substitution of glutamine by histidine in AP0A4. Its minor allele carriers (n=57) 
had marginally lower TC (?=0.06) and TG (P=0.07) levels as compared with those 
of non-carriers (n=336) in the Caucasian control subjects (Fisher, Burke et al. 1999). 
1.5.1.4 Apolipoprotein A5 gene 
Apolipoprotein A5 gene (AP0A5) is a newly discovered member of the 
apolipoprotein gene family (Figure 5). Apolipoprotein A5 (apoA5) is synthesized in 
the liver and revealed by comparative sequencing of human and mouse genomes 
(Pennacchio, Olivier et al. 2001). It was confirmed to locate on chromosome l lq23 
and consist of four exons encoding an 1107 bp open reading frame (van Dijk, Rensen 
et al. 2004). The size and molecular weight of the apoA5 is 343 amino acids and 39 
KDa respectively (van Dijk, Rensen et al. 2004). Pennacchio et al have shown that 
AP0A5 transgenic mice (AP0A5 overexpressers) displayed a decrease in TG levels 
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by approximately 66% (Pemiacchio, Olivier et al. 2001). In contrast, AP0A5 
knockout mice were observed to have 4-fold higher TG levels than controls 
(Pennacchio, Olivier et al. 2001). Mice with adenoviral vectors containing AP0A5 
developed a 20-fold increase in plasma apoA5 levels (van der Vliet, Schaap et al. 
2002). The mice were reported to have not only a 70% reduction in TG levels and 
but also a 40% reduction in TC levels (van der Vliet, Schaap et al. 2002). As the 
transgenic mice in Pennacchio's study were not found to have a reduction in TC 
levels, it was still unknown whether the reduction in TC levels was associated with 
the extremely high (20-fold) apoA5 levels in the adenovims-treated mice. 
Figure 5. AP0A5 genomic structure and SNP locations. Exons and protein-encoding 
regions are shown by black shaded boxes. The positions and identities of the AP0A5 
SNPs are also shown. The figure is adapted from the study of Pennacchio et al 
(Pennacchio, Olivier et al. 2002). 
AP0A5 
—— • 
5'UTR Start Condon Stop codon 3 'UTR 
Promoter H ^ ^ H 
rs662799 ^ rs2072560 
-1131 T>C rs651821 IVS3+4760A rs2266788 
(SNPS) -3A>G (Kozak) (SNP2) 1259T>C (SNPl) 
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Several functional studies were performed to explain the triglyceride lowering 
activity of apoA5. It displays high affinity, low elasticity and slow binding kinetics at 
hydrophobic interfaces. This may retard triglyceride-rich particle assembly, or act as 
an intracellular "brake" on hepatic lipid export (Weinberg, Cook et al. 2003; Schaap, 
Patrick et al. 2004). Apolipoprotein A5 was also described to interact with 
lipoprotein lipase to increase its activity significantly, so the TG levels were lowered 
(Fruchart-Najib, Bauge et al. 2004; Merkel, Loeffler et al. 2005). It was also proved 
to reduce TG levels by both reducing hepatic VLDL production rate and enhancing 
the lipolytic conversion of TG-rich lipoproteins (Schaap, Patrick et al. 2004). 
Recently, Nowak et al have shown that hyperinsulinemia can lower the plasma 
apoA5 levels resulting in hypertriglyceridemia (Nowak, Helleboid-Chapman et al. 
2005). Previous studies have also observed that AP0A5 knockout mice have 41% 
increased HDL-C levels, meanwhile overexpression of AP0A5 dose-depeiidently 
decreases HDL-C levels (Schaap, Patrick et al. 2004; Grosskopf, Baroukh et al. 
2 0 0 5 ) . 
Nowadays, a novel sandwich enzyme-linked immunosorbent assay (ELISA) is 
developed to measure plasma apoA5 level in humans (Ishihara, Kujiraoka et al. 
2005). The lipid-lowering effects of apoA5 in mice have suggested that plasma 
apoA5 levels may correlate negatively with plasma lipid levels in humans. 
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Unexpectedly, significant positive correlations between apoA5 and TG levels have 
been observed in some human studies (Henneman，Schaap et al. 2006; Schaap, 
Nierman et al. 2006; Vaesseii, Schaap et al. 2006). Schaap et al have found that the 
plasma apoA5 levels in Caucasian HTG patients (n=28) were significantly higher 
than these in normal controls (n=42) (1,987 vs 258 ng/ml； P<0.001)，so apoAS levels 
were positively correlated with TG levels (r = +0.44,户=0.02) (Schaap, Nierman et al. 
2006). 
The minor allele ofrs651821 (APOAS -3 A>G) was associated with elevated TG, 
and LDL-C levels and decreased HDL-C levels in a general Singaporean Chinese 
population (n= 1,220)(户<0.0001，P<0.001 and P=0.0205 respectively) (Lai, Tai et al. 
2003). Though it was not associated with FCH in Caucasian probands (Mar, 
Pajukanta et al. 2004), its minor allele was found to be a strong independent 
predictor of HTG (OR=3.23,尸<0.001) in Caucasian HTG patients (n=84) as 
compared with controls (n=106) (Wright, Young et al. 2005). The minor allele of 
rs662799 (AP0A5 -1131 T>C, SNP3) was associated with elevated TG levels 
(Aouizerat，Kulkarni et al. 2003; Baum, Tomlinson et al. 2003; Lai, Tai et al. 2003; 
Bi, Yaii et al. 2004)，increased risk of CAD (0R=1.8) (Bi，Yaii et al. 2004) and CH in 
Chinese (?=0.0002) (Aouizerat, Kulkarni et al. 2003). It was also associated with 
elevated TG levels in other Asian populations such as Japanese (Endo，Yanagi et al. 
2 1 
2002) and Koreans (Jang, Kim et al. 2004). In Caucasians, the minor allele was 
associated with FCH probands (n=103) (OR=3.25) (Ribalta, Figuera et al. 2002), but 
Mar and colleagues did not find its association with FCH (Mar, Pajukanta et al. 
2004). A Taiwan study has shown significant differences in the genotype and allele 
frequencies of rs2072560 (IVS3 +476 G>A, SNP2) between the HTG subjects 
(n=290) and controls (n=303) in Chinese (P<0.001) (Kao, Wen et al. 2003). In 
Singaporean Chinese (n= 1,220)，a strong association was also found between the 
minor alleles and elevated TG levels (P<0.0001) (Lai, Tai et al. 2003). It was 
reported that rs2Q75291 (AP0A5 553 G � T ) was associated with the increased risk of 
developing HTG (OR=11.73, ？<0.0001) (Kao, Wen et al. 2003) and CAD 
(OR=2.089, P=0.017) in Chinese (Tang, Sun et al. 2005). The SNP rs2266788 
(AP0A5 1259 T>C, SNPl) was associated with increased TG levels and decreased 
HDL-C levels in Chinese (Kao, Wen et al. 2003; Lai, Tai et al. 2003). 
Pennacchio et al have found three common AP0A5 haplotypes (AP0A5*1, 
APOA5*2, APOA5*3) and their relative frequencies in 419 Caucasian samples 
(Berkley Lipid Study Population) (Table 2) (Pennacchio, Olivier et al. 2002). The 
haplotypes consisted of five AP0A5 SNPs (rs662799. rs651821, C . 5 6 0 G . 
rs2Q72560, rs2266788) in strong LD (Pennacchio, Olivier et al. 2002). The minor 
allele of rs662799 (SNPS) was used as a marker to define APOA5*2, whereas the 
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minor allele of c.56C>G (S19W) was used to define APOA5*3 (Table 2). The 
haplotype APOA5*2 defined by rs662799 was associated with a 30% elevation of 
plasma TG levels in random unrelated normolipidemic Caucasians (Peiinacchio, 
Olivier et al. 2001). The average TG level of rs662799 minor allele earners (n=72) 
was 153.1 mg/dl that was significantly higher than this of rs662799 major allele 
homozygotes (113.0 mg/dl) (n=354). In the stratified population of the same study, 
APOA5*2 was found to have 3-fold increased frequency in individuals from the high 
triglyceride group (>90出 percentile) versus the low one (<10 '^^  percentile) (22.3% vs 
6.7%) (Pennacchio, Olivier et al. 2001; Pennacchio, Olivier et al. 2002). The strong 
association between APOA5*2 and increased plasma TG levels was also confirmed 
by the Northwick Park Heart Study and the Dallas Population Study (Pennacchio, 
Olivier et al. 2002; Talmud, Hawe et al. 2002). The study results of Lai et al have 
indicated that the haplotypes carrying the minor alleles of rs662799 and rs651821 
had major effects on elevated TG levels in general Singaporean Chinese (Lai, Tai et 
al. 2003). 
23 
Table 2. Three common AP0A5 haplotypes and their relative frequencies in 419 
Caucasian samples (Berkeley Lipid Study Population). The minor alleles of the 
haplotypes are highlighted in bold. The table is copied from the study of Pennacchio 
et al (Pennacchio, Olivier et al. 2002). 
rs662799 rs2072560 rs2266788 
Frequency rs651821 c.56 C>G 
Haplotype -1131 T>C 1VS3 +476 1259 T>C 
(o/o) -3 A>G S19W 
SNPS O A SNP2 SNPl 
APOA5*] 81 .6 T A G G T 
APOA5*2 8.0 C G C A C 
APOA5*3 8 .0 T A G G T 
1.5.2 Upstream transcription factor 1 gene 
Linkage of FCH to chromosome Iq21-q23 was identified in Finnish, German and 
Chinese families (Pajukanta, Nuotio et al. 1998; Pei, Baron et al. 2000). Upstream 
transcription factor 1 gene (USFl), located in the chromosome Iq21-q23, has been 
reported by the Finnish family study to be associated with FCH (Pajukanta, Lilja et al. 
2004). In the study, rs3737787 rUSFlsl), rs2Q73658 (USFlsTt and their combined 
haplotype usf ls l -usf ls2 were found to be associated strongly with FCH in 60 
extended FCH families (n=721) (?=0.00002), especially in males with high TG 
levels (P=0.0000009) (Pajukanta, Lilja et al. 2004). Coon et al have proved that 
rs3737787 is associated with FCH (户=0.02), and quantitatively with triglycerides 
(尸=0.02) and LDL-C (P=0.02) in 87 Caucasian pedigrees (Coon, Xin et al. 2005). 
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Associations of the haplotype usflsl-usfls2 with FCH (户=0.03) and TG levels 
(P=0.006) were also reported in 24 Mexican families (Hueitas-Vazquez, 
Aguilar-Salinas et al. 2005). 
USFl regulates the important enzymes of glucose and lipid metabolism in the 
liver, pancreas and adipose tissue that has been identified as the prime candidate for 
increasing susceptibility to FCH, type 2 diabetes and MES {Pajukanta, Lilja et al. 
2004). The exact functions of USFl variants in the phenotypic expression of FCH 
are still unknown. Recently, an animal study has demonstrated that insulin treatment 
can reduce USFl to bind with E-box at the AP0A5 promoter (Nowak, 
Helleboid-Chapman et al. 2005). The downregulated AP0A5 and reduced apoA5 
levels can elevate TG levels in FCH patients (Nowak, Helleboid-Chapman et al. 
2005). 
1.5.3 Lipoprotein lipase gene 
Lipoprotein lipase catalyzes the hydrolysis of Cm and VLDL particles by 
removing their core triglycerides (Goldberg 1996). Furthermore, the plasma HDL-C 
concentration can also be affected by lipoprotein lipase-catalyzed VLDL metabolism 
(Patsch，Gotto et al. 1978). As lipoprotein lipase plays an important role in the major 
pathway of both VLDL and HDL metabolism, human lipoprotein lipase gene (LPL) 
on chromosome 8p22 has been studied extensively for its association with lipid 
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metabolism and CAD. 
The minor allele of rs320 (LPL intron 8, Hind III) was found to be associated 
with HTG (Chamberlain, Thorn et al. 1989; Thorn, Chamberlain et al. 1990; Mattu, 
Needham et al. 1994; Tu, Tu et al. 2005), hypercholesterolemia (Heinzmann, 
Kirchgessner et al. 1991; Larson, Hoffmann et al. 1999), increased apoB (Mattu, 
Needham et al. 1994) and premature CAD (Thorn, Chamberlain et al. 1990; Mattu, 
Needham et al. 1994; Chen, Patsch et al. 1996). The minor allele of LPL S447X was 
reported to protect against high TG levels, low HDL and premature CAD (OR=0.43, 
户=0.04) in the Frainingham Offspring Study (Larson, Hoffmann et al. 1999). It has 
also been shown to reduce the atherogenic risks (adjusted OR=0.39，95% CI) 
(Morabia, Cayanis et al. 2003). 
1.5.4 Peroxisome proliferator-activated receptor y gene 
Peroxisome proliferator-activated receptors, mainly found in adipose tissue, is 
one of a group of transcription factors involved in different aspects of metabolic 
control (Kliewer and Wilson 1998). They play a crucial role in adipocyte 
differentiation, fat storage and glucose homeostasis (Kliewer and Wilson 1998; 
Martin, Schoonjans et al. 1998). The peroxisome proliferator-activated receptor y 
gene (PPARy) at 3p25-24 has four isoforms: PPARy 1, PPARy2, PPARy3 and PPARy4 
(Fajas，Auboeuf et al. 1997; Fajas，J.C. et al. 1998; Simdvold and Lien 2001). They 
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are all expressed in adipose tissue regulating adipocyte differentiation, so PPARy is a 
potential candidate gene for FCH, CH and CAD. 
The minor allele carriers (n=196) of 1 6 1 0 T were found to have significantly 
reduced CAD risk (OR=0.457, ？=0.0045) compared to the major allele homozygotes 
(n=451) (Wang, Oosterhof et al. 1999). The minor allele of - 6 8 1 0 G was also 
reported to be associated with increased TC, LDL-C and apoB levels in a French 
population (n=836) (Meirhaeghe, Fajas et al. 2003). 
1.5.5 a-adducin gene 
Adducin, an a/p heterodimeric protein, regulates cell-signal transduction through 
changes in the actin cytoskeleton (Hughes and Bennett 1995; Matsuoka, Hughes et al. 
1996). It was reported that rs4961 (Gly460Trp) on a-adducin gene (ADDl) was 
associated with FCH in Caucasians (Beeks, Janssen et al. 2001). The number of 
subjects carrying its minor allele was significantly higher in FCH patients (n=79) as 
compared with controls (n=121) (53% vs 33%, ？=0.018) (Beeks, Janssen et al. 
2001). 
1.5.6 SNPs selected from the haplotype map 
Recently, a haplotype map (HapMap) of the human genome has been reported by 
the International HapMap Consortium (The International SNP Map Working Group 
2001; The International HapMap Consortium 2003). It is a huge public database 
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having more than one million SNPs genotyped from four populations i.e. US 
Caucasians, Nigerians, Japanese and Chinese (The International SNP Map Working 
Group 2001; The International HapMap Consortium 2003). The goal of the 
International HapMap Project is to develop a research tool as a shortcut for 
researchers to c a n y out candidate-gene, l inkage-based and g e n o m e - w i d e assoc ia t ion 
Studies. It can facilitate them to discover the genetic factors contributing to disease 
susceptibility more efficiently. 
In this study, some SNPs were selected from the HapMap for discovering novel 
findings. SNPs that were proved to be significantly associated with FCH in previous 
studies i.e. rs662799 on APOAl/C3/A4/A5 gene cluster, rs3737787 on USFl and 
rs320 on LPL were selected as reference SNPs. SNPs close to the reference SNPs on 
the same gene sequence, and with the Chinese minor allele frequency above 10%， 
were selected as candidate SNPs. Using this approach, three SNPs (rs6589567, 
rs6589568, rs 1729410) from APOA4-A5, two SNPs (rs2774276. rs6656547) from 
USFl and two SNPs (rs327, rs297) from LPL were selected. 
1.6 Objectives 
It has been suggested that the SNPs mentioned above are associated with FCH, 
CAD and elevated lipid levels in Caucasians. They have also been associated with 
CAD and elevated lipid levels in Chinese. To my knowledge, no studies were found 
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regarding the associations between these SNPs and FCH or CH in Chinese. Though 
some associations have already been found between the SNPs and FCH in 
Caucasians, the minor allele frequency of the same SNP can be different among 
different ethnic groups such as Caucasians, Asians and blacks. Hence, this study aims 
to investigate whether these SNPs are specifically associated with FCH or CH in 
Chinese. A total of 25 SNPs were selected from 5 candidate genes (Table 3) i.e. 14 
SNPs from APOA1/C3/A4/A5 gene cluster, four SNPs from USFl, four SNPs from 
LPL，two SNPs from PPARy and one SNP from ADDl. FCH or CH associated SNPs 
can be used as potential prognostic indicators clinically. They may also help to 
indicate the underlying genetic mechanisms of FCH and CH pathogenesis. 
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Table 3. Twenty-five SNPs were selected from five candidate genes to test for their 
associations with FCH or CH in Chinese. Underlined SNPs were selected 
from the HapMap. 
APOA1/C3/A4/A5 gene cluster 
APOAl APOC3 APOA4 APOA4-A5 APOAS USFl LPL PPARy ADDl 
1.S675 rs320 rs4961 
rs5070 rs4520 rs651821 rs3737787 161 
347 A>T rs6589567 Intron 8 Gly460 
317 O T 1100 O T -3 A>G si C �丁 
(Hinfl) Hind III Tip 
rs5128 rs662799 
rs2073658 -681 




rs2854116 ^ IVS3+476 
rs 1729410 rs2774276 rs327 
-455 T>C G>A 
SNP2 
rs2075291 




I I I SNP� I I I 
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Chapter 2 Materials and Methods 
2.1 Overview 
FCH and CH are multi-factorial and polygenic lipid disorders, so we designed a 
case-control association study using SNP based candidate gene analysis that has a 
better chance to detect the small effects of the multiple gene variants. Primary 
hyperlipidemia patients attending the lipid clinic, mainly lipid phenotype IIA，IIB 
and IV, were recruited in the lipid clinic of the Prince of Wales Hospital between 
1995 and 2000. The patients were also asked to invite their family members to join. 
As not all family members were willing to join the study, some families had only one 
proband. All participants gave a written informed consent to join the study 
voluntarily. FCH or CH cases were selected from the recruited subjects according to 
the diagnostic criteria. The DNA specimens of age-gender matched normal controls 
were collected from the control groups used in other clinical studies including a 
stroke and a hypertension study. All patients and controls were of Han Chinese origin 
and lived in the Hong Kong Special Administration Region of China. 
Firstly, all participants were asked to do a Genetic Hyperlipidemia Survey 
questionnaire for providing some basic personal information. Afterwards, their body 
conditions were assessed by a physical examination and some biochemical 
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measurements. All patients and normal controls were selected from the recruited 
subjects by using a number of diagnostic and exclusion criteria. DNA samples of the 
selected patients were extracted from their blood specimens by either the traditional 
phenol chloroform method or the High Pure PGR Template Preparation kit (Roche). 
The DNA samples of the age-sex related normal controls were taken from some other 
studies such as a stroke study and a hypertension study. All DNA samples were sent 
to the Hong Kong University Genome Research Centre for genotyping 25 SNPs on 
five candidate genes by the high-throughput MassARRAY system. Finally, the 
genotyping results were analyzed by the programs of SPSS 13.0 (SPSS Inc.) and the 
Haploview (Daly Lab.). 
2.2 Routine assessments 
2.2.1 Genetic Hyperlipidemia Survey 
All participants were asked to do a Genetic Hyperlipidemia Survey questionnaire. 
Besides providing some basic personal information such as name, age, gender and 
address, they were also requested to report their past illness and recent drug 
treatments in detail. Furthermore, they were asked to invite their first-degree relatives 
to join the study. They were also asked whether any of their family members suffered 
from heart disease, stroke, diabetes or hypertension. 
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2.2.2 Physical examinations 
All subjects' weight and height were measured in kilograms (kg) and centimeters 
(cm) respectively. Body mass index (BMI) could be calculated by using the formula 
BMI (kg/m') = weight (kg) / height^ (m^). Systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) were measured in millimeter of mercury (mmHg) by 
the Critikon Dinamap automatic sphygmomanometer (Critikon Inc, CA USA). After 
a resting period of 10 to 15 minutes, blood pressure in the sitting position was 
measured in triplicate at one-minute intervals. 
2.2.3 Biochemical measurements 
2.2.3.1 Fasting plasma cholesterol 
Total cholesterol (TC) level was measured by the enzymatic method (Centrichem 
chemistry System, Baker Instruments Co. Allentown). Esterified cholesterol is 
hydrolyzed by cholesterol esterase to release free cholesterol that is further oxidized 
by cholesterol oxidase to release hydrogen peroxide. The hydrogen peroxide reacts 
with a chromogen to give a measurable color change at 540nm. HDL-C level was 
determined by using the fractional precipitation of dextran sulphate with manganous 
ion. LDL-C level was estimated by using the Friedewald's formulae (VLDL = TG/5, 
LDL-C = TC - HDL-C - TG/5). The equations are only valid for specimens in which 
TG levels are below 4.5mmol/L. 
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2.2.3.2 Fasting plasma triglyceride 
TG level was measured by the glyceryl dehydrogenase reaction after hydrolyzing 
the triglyceride (Centrichem Chemistry System, Baker Instruments Co., Allentown). 
2.2.3.3 Fasting plasma glucose 
Fasting plasma glucose (FBG) level was measured by using a standard glucose 
oxidase method. 
2.3 Subjects 
2.3.1 FCH cases 
Fifty-six genetically unrelated FCH patients (11 phenotype IIA, 35 phenotype IIB, 
10 phenotype IV) were selected from the recruited subjects. There were 27 males and 
29 females with a mean age of 49.6 ± 12.3 ( ± 1 standard deviation, 1 SD). They all 
had elevated TC levels (TC > 6.2 mmol/L) and/or elevated TG levels (2mmol/L < 
TG <= 15 mmol/L). All patients had at least one first-degree relative who had lipid 
phenotype IIB, or a lipid phenotype different from those of probands. Some studies 
used elevated TC and/or TG levels above percentile or elevated apoB levels 
above percentile as cutoff points to define FCH cases (Pajukanta, Nuotio et al. 
1998; Aouizerat, Allayee et al. 1999; Hopkins, Heiss et al. 2003; Eichenbaum-Voline, 
Olivier et al. 2004). As these data were unavailable locally, this study used the 
absolute values of TC and TG levels to define FCH cases. Patients with diabetes 
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(FPG > 7mmol/L), renal, liver or thyroid disorder were excluded. 
2.3.2 CH cases 
One hundred and fifteen genetically unrelated CH patients (all phenotype IIB) 
were selected. There were 53 males and 62 females with a mean age of 52.6 土 12.9 
(土 1 SD). Thirty-five FCH patients having lipid phenotype IIB were also defined as 
CH cases simultaneously (Figure 6). All CH patients had elevated TC levels ( T 0 6 . 2 
mmol/L) and TG levels (2mmol/L < T G <= 15 mmol/L). Patients with diabetes (FPG 
> 7mmol/L), renal, liver or thyroid disorder were excluded. 
Figure 6. The number of patients who were defined as FCH and / or CH cases 
35 patients were defined 
as both FCH and CH cases 
56 FCH / 115 CH 
cases cases , 
21 patients were defined 80 patients were defined 
as FCH cases as CH cases 
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2.3.3 Normal controls 
The mean age of 176 normal controls (61 males, 115 females) was 50.1 土 9.4 
(土 ISD). All controls had normal TC (TC < 5.2 mmol/L) and TG levels (TG < 2.0 
mmol/L). Any subjects with diabetes (FBG > 7mmol/L) or hypertension (SBP > 
140mmHg, DBP > 90mmHg) must be excluded. 
2.4 DNA extraction from blood specimens 
The DNA samples were extracted from the blood specimens by either the 
traditional phenol chloroform method or the High Pure PGR Template Preparation 
Kit (Roche). 
2.4.1 Phenol chloroform method 
The protocol of the phenol chloroform method was as follows: (IJ Lysis buffer 
was added to the blood up to 25ml and placed on ice for 15 minutes. After 
centrifuging at 3000i.pm, 4°C for 15 minutes, the supernatant was then decanted. {2} 
The cell pellet was resuspended in lysis buffer up to 25ml and step (1) was repeated. 
Q} The cell pellet was resuspended in 3ml of TE buffer, then 600ul of 10% SDS and 
50ul proteinase K (1 Omg/ml) was added to incubate at 60°C in a water bath 
overnight. (4} One milliliter of 6M NaCl was added to the overnight digested sample 
with vigorous shaking for a few seconds. Then, the sample was centrifuged at 
3000rpm, 4°C for 10 minutes. The supernatant was decanted to a clean test tube 
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and 1 ml of TE equilibrated phenol was added and mixed well. Then, 1 ml of 
chloroform was added and mixed well. The mixture was centrifuged at SOOOrpm, 
4°C for 10 minutes. The upper aqueous layer was transferred to a new test tube. (6) 
Two milliliters of chloroform was added and mixed well. The mixture was 
centrifuged at 3000rpm, 4°C for 10 minutes. The upper aqueous layer was 
transferred to a new test tube for DNA precipitation. (7) After two volumes of ice 
cold absolute alcohol was added, DNA started to precipitate as a stringy mass. 
The precipitated DNA was transferred to a 1.5ml screw cap tube and washed with 
1ml 70% alcohol. After being centrifuged for 10 minutes at 14,000 rpm, the DNA 
was pelleted to the bottom of the tube and the alcohol was drained off. (9) The DNA 
was briefly dried at room temperature, and then thoroughly dissolved in TE buffer. 
Finally, the absorbance of the DNA at 260nm and 280nm was measured. DNA with a 
ratio of 1.8 was regarded as good quality. 
2.4.2 High Pure PGR Template Preparation Kit (Roche) 
The protocol of the High Pure PGR Template Preparation Kit (Roche) was as the 
follows. (T) Two hundred microliters blood, 200ul binding buffer and 40ul Proteinase 
K were mixed and incubated in a 1.5ml microcentrifuge tube for 10 minutes at 70 °C. 
(2) One hundred microliters isopropanol was added and mixed. The entire sample 
was moved to the upper reservoir of the combined High Pure Filter collection tube. 
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The tube was centrifbged for 1 minute at 8000g. 0 } The filter tube was combined 
with a new collection tube. Five hundred microliters inhibitor removal buffer was 
added to the upper reservoir and centrifuged for 1 minute at 8000g. (4} Five hundred 
microliters wash buffer was added to the upper reservoir. Then, it was centrifuged for 
1 minute at 8000g. Step (4) was repeated once more. The flowthrough was 
discarded. The filter tube was centrifuged for 10 seconds at approximately 13,000g to 
remove residual wash buffer. [6} The DNA was eluted by adding 200ul prewarmed 
(70°C) elution buffer to the upper reservoir and centrifuging for 1 minute at 8000g. 
2.5 Genotyping by the MassARRAY system 
The MassARRAY system, developed by the Sequenom Inc., has four main 
steps to do high-throughput genotyping. £1} Template amplification is the first step. 
Approximately 2.5ng DNA containing the SNP site of interest is amplified in a 5ill 
volume using a 384-well microtiter plate format. (2} Dephosphorylation is the second 
step. Arctic shrimp alkaline phosphatase is added to samples to dephosphorylate any 
residual amplification nucleotides that can prevent their future incorporation and 
interference with the primer extension assay. The Homogenous MassEXTEND 
(hME) assay, as a critical component of the MassARRAY system, is the third step 
(Figure 7). The MassENTEND primer, DNA polymerase, and a mixture of 
deoxynucleotides (dNTPs) and dideoxynucleotide triphosphates (ddNTPs) are added 
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to initiate the hME assay. Each of the primer extension products has a unique 
molecular weight that can be measured directly by using the mass spectrometry. 
Hence, the associated genotypes can be identified precisely. (4) Genotyping calling 
and bioinformatics are the final steps. The SpectroCHIP is placed into the 
MALDI-TOF, and the mass and their correlating genotypes are determined in real 
time with MassARRAY RT software. 
Figure 7. The Homogenous MassEXTEND (hME) assay. A specifically designed 
extend primer is hybridized close to the SNP polymorphic site. Deoxynucleotides 
(dNTPs) are incorporated through the polymorphic site until a dideoxynucleotide 
(ddNTP) terminates the reaction. As the termination point and number of nucleotides 
are sequence specific, the mass of the extension products can be measured by the 
mass spectrometry. The figure is adapted from the webpage of the Sequenom Inc.. 
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2.6 Statistical analyses 
2.6.1 Overview 
The data of the study were analyzed by various statistical tests of the SPSS 13.0 
program (SPSS Inc.). Student's t-test was used to compare the differences of the 
characteristics between cases and controls. Pearson's Chi-square test was used to 
examine the differences of genotypic distribution and allelic frequency between cases 
and controls. Chi-square goodness-of-fit test was used to assess the Hardy-Weinberg 
equilibrium (HWE) of cases and controls separately. To eliminate confounding 
influences, the binary logistic regression test was used to determine FCH or CH risk 
(estimated by the OR with 95% CI) with adjustment for conventional risk factors 
including age, gender and BMI. Means of plasma lipid levels, FPG, SBP and DBP 
were compared among different genotypes by the analysis of covariance (ANCOVA) 
adjusted for age, gender and BMI. Finally, the Haploview program (Daly Lab.) 
(Barrett, Fry et al. 2005) was used to do the haplotype case-control association tests. 
In this study, a two-tailed P value less than 0.05 (P<0.05) was considered statistically 
significant. The Bonferroni's correction was used to account for multiple 
comparisons. The P values lower than the significance levels adjusted with the 
BonfeiToni's correction were stated. 
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2.6.2 Student's t-test 
Student's t-test determines whether the means of two sets of normally distributed 
data are statistically different. In this study, the t-test was used to assess whether the 
means of the characteristics of cases and controls were different from each other. If 
the P value was less than 0.05, the means of two groups were statistically different, 
and vice versa. 
2.6.3 Pearson's Chi-square test 
Pearson's Chi-square test is the original and widely-used Chi-square test that is 
used to assess two types of comparisons: tests of goodness of fit and tests of 
independence. A test of goodness of fitness examines whether an observed frequency 
distribution differs from a theoretical distribution. A test of independence assesses 
whether the observations on two variables are independent of each other. In this 
study, the Chi-square independence test compared the genotypic distribution and 
allelic frequency between cases and controls. If the P value was less than 0.05, the 
observed frequency distributions of two groups differed significantly from each other, 
and vice versa. 
2.6.4 Hardy-WeiIIberg equilibrium 
Hardy-Weinberg equilibrium (HWE) named after G. H. Hardy and Wilhelm 
Weinberg, states that random mating results in an equilibrium of genotypes after only 
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one generation, so genetic variation is maintained (Griffiths 2004). For example, a 
single locus with two alleles A and a with allele frequencies of p and q respectively, 
the HWE predicts that the genotypic frequencies for the AA homozygote to be p^, the 
Aa heterozygote to be 2pq and the other aa homozygote to be q^. Genotyping errors 
or non-random mating caused by inbreeding and small population size can affect a 
population violating the HWE. 
Chi-square goodness-of-fit test is generally used to test deviation from the HWE. 
It compares the observed genotype frequencies obtained from the data and the 
expected genotype frequencies obtained using the HWE. In this study, the test was 
used to examine whether the observed genotype frequencies of cases and controls 
were in HWE separately. The 5% significance level for first degree of freedom was 
3.84. If the Chi-square value was less than 3.84，it indicated that the genotype 
frequencies should be in HWE, and vice versa. 
2.6.5 Binary logistic regression test 
Logistic regression is part of a category of statistical models called generalized 
linear models. It can be used to predict a discrete outcome (dependent variable) from 
a set of independent variables in any form such as discrete, continuous or 
dichotomous. The outcome is usually dichotomoiis (binary) i.e. disease/no disease or 
success/failure. The binary logistic regression test uses odds ratio (OR) to analyze the 
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probability of developing diseases. Odds ratio is defined as the ratio of odds of an 
event occurring in one group to the odds of it occurring in another group. An OR 
greater than one indicates that the chance is higher in one group compared with the 
reference group. An OR less than one indicates that the chance is lower in one group 
compared with the reference group. In this study, the binary logistic regression test 
was used to determine the risk of developing FCH or CH among different genotypes 
after adjusted to other confounding factors such as age, gender and BMI. 
2.6.6 Analysis of covariance 
Analysis of covariance (ANCOVA) is a merger of ANOVA and regression for 
continuous variables. It can be used to compare the means of certain factors after 
adjusted to their covariates. The inclusion of covariates can increase statistical power 
because they also account for some of the variability. In this study, ANCOVA was 
used to compare the means of the lipid levels, FPG and blood pressure among 
different genotypes adjusted for age, gender and BMI. If the Levene's homogeneity 
of variance test suggests that the data of the TG levels are not normally distributed, 
they must be log-transformed to correct the skewness of the observed data. 
2.6.7 Haplotype analysis 
The specific set of SNPs found to be statistically associated (in strong LD) on a 
single chromosome, is called a haplotype (The International HapMap Consortium 
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2003). As the identification of a disease- associated haplotype can help to predict the 
information about the remainder of the SNPs in the region, haplotype analysis is 
valuable to increase the statistical power for detecting a disease gene. 
Haploview (Daly Lab.) (Barrett, Fry et al. 2005) is a program that can compute 
multi-marker haplotype case control association tests automatically. In this study, the 
haplotype analysis was performed on the haplotype blocks defined by the default 
confidence intervals algorithm of the Haploview. According to the default setting, 
95% confidence bounds on D prime were generated and each comparison was called 
"strong LD". A haplotype block was created if 95% of informative (i.e. 
non-inconclusive) comparisons were "strong LD" ( L 0 D ^ 2 , D’ =1). The counts for 
the case-control association tests are obtained by summing the fractional likelihood 
of each individual for each haplotype. For example, if a particular individual is 
determined by the expectation-maximization (EM) algorithm to have a 30% 
likelihood of haplotype A and 70% likelihood of haplotype B，0.3 and 0.7 are added 
to the count for A and B respectively. 
2.6.8 Bonferroni's correction 
Bonferroni's correction is widely used to adjust the type I error caused by the 
multiple comparisons. Type I error can increase the chance of wrongly declaring a 
significant difference when it is not true. Bonferroni's correction is thought to be a 
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convenient, but also over conservative way to adjust the P values (Rotliman 1990; 
Perneger 1998; Perneger 1999). In this study, the P values lower than the 
significance levels adjusted with the Bonferroni's correction were stated. If n SNPs 
were tested for association, the significance level adjusted with the correction is 0.05 
divided by n (0.05/ii). For haplotype analysis, the SNPs in strong LD with each other 
were not considered as independent tests. The significant levels adjusted with the 
correction are equivalent to 0.05 divided by the number of groups of SNPs in 
complete LD (Mar, Pajukanta et al. 2004). 
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Chapter Three Results 
3.1 Overview 
First of all, the characteristics of the study population were compared by the 
Student's t-test and the Chi-square test. The genotyping results of 25 SNPs on 5 
candidate genes were analyzed by a stepwise approach. Insignificant SNPs were 
eliminated after going through every statistical step, so only significant SNPs were 
further analyzed. Firstly, the Chi-square goodness-of-fit test was used to select the 
SNPs in HWE. The Chi-square values of the selected SNPs must be above 3.84(x^ 
>3.84) for cases and controls separately. Secondly, the Pearson's Chi-square 
independence test was used to select the SNPs with significant different genotypic 
distribution and allelic frequency between cases and controls. P values of the 
selected SNPs must be less than 0.05 (户<0.05). Thirdly, the binary logistic regression 
test was used to select the SNPs that had FCH or CH risk genotypes (significant 
higher ORs compared with the reference genotype). P values of the selected SNPs 
must be less than 0.05 (95% CI, P<0.05) adjusted for age, gender and BMI. Finally, 
SNPs were analyzed for parameters and haplotypes by ANCOVA and Haploview 
respectively. The stepwise approach could help to present the large amount of 
genotyping data in a logical and readable manner. 
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3.2. Characteristics of the study population 
3.2.1 FCH cases versus controls 
Comparisons of the characteristics between FCH cases and controls by the 
Student's t-test were listed in the table 4. FCH cases were age-gender matched with 
the controls (戶〉0.05) (Table 4). Male/female ratio of FCH cases was barely matched 
with this of controls because of some limitations. The controls were taken from other 
projects instead of recruiting ourselves. Moreover, we had limited number of FCH 
cases, so we increased the statistical power of the study by using more controls. FCH 
cases had significant higher TC, TG, LDL-C levels and lower HDL-C levels 
compared with these of the controls (户<0.001) (Table 4). FCH cases also had 
significant higher BMI, FPG, SBP and DBP (户<0.05) (Table 4). There was a 
significant difference in age between male cases and controls (户=0.009) (Table 5). 
After analyzing the characteristics of different genders separately, the results showed 
that there were no gender related differences among these characteristics (Table 5). 
The results also indicated that obesity (high BMI), hyperglycemia (high FPG) and 
hypertension (high SBP, DBP) are the common metabolic abnormalities of FCH. 
There should be quantitative but not qualitative differences between the phenotypic 
features of Chinese and Caucasian FCH patients. 
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Table 4. Characteristics of FCH cases versus controls 
Trait Controls FCH cases P value 
Number 176 56 NA 
M/F 61/115 27/29 0.069 
Age 50 .1±9.4 49.6 ± 12.3 0.768 
BMI (kg/m^) 23.6 ±3 .3 25.2 ±3 .1 0.001* 
TC (mmol/1) 4.5 土 0.5 7.2 ±1 .6 <0.001* 
TG (mmol/1) 0.9 ±0 .4 3.5 ±2 .5 <0.001* 
HDL-C (mmol/1) 1.5 土 0.3 1.2 土 0.4 < 0 . 0 0 1 * 
LDL-C # (mmol/1) 2.6 ±0.5 4.9 ±1 .7 <0.001* 
FPG (mmol/1) 5.0 ±0 .5 5.2 ± 0 . 7 0.03* 
SBP(mmHg) 115 ± 1 2 132 ± 1 7 <0.001* 
DBP (mniHg) 68 ± 9 77 ± 1 1 <0.001* 
Data represent means 土 SD 
P values were calculated by the Student's t-test and Chi-square test. * 户 < 0 . 0 5 
# As the Friedewald's formulae for calculating LDL-C are only valid for specimens 
in which TG < 4.5 mmol/L, only 47 out of 56 FCH cases have valid LDL-C readings. 
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Table 5. The characteristics of FCH cases versus controls in different genders 
Trait Males Females 
Controls FCH cases Controls FCH cases 
Number P value P value 
(n=61) (n=27) (n=115) (n=29) 
Age 52.4 ±10 .1 46.1 ± 10.2 0.009* 48.9 ± 8.8 52.8 ± 1 3 . 3 0.143 
— ^ ― — ^ ― ^ ― ^ ^ ― — — ^ ― — — — — ^ ^ ^ ― — — — ； 
BMI (kg/m-) 2 3 . 8 ± 3 . 2 25.1 土 2 . 9 0.055 23.5 3 25.3土3.4 0.014* 丨 
TC (mmol/1) 4.6 土 0.4 7 . 0 ± 1 . 8 <0.001* 4 . 5 ± 0 . 5 7.5 土 1.3 <0.001* 
TG (mmol/I) 1.0 ± 0 . 4 3.3 ±1.5 <0.001* 0.9 ± 0 . 3 3.6 ± 3 . 2 <0.001* 
HDL-C 
1.4 土 0.3 1.0 ± 0 . 2 <0.001* 1.5 土 0.4 1.3 ± 0 . 4 0.002* 
(mmol/1) 一 一 
LDL-C # 
2.8 土 0.5 4.7 ± 1 . 9 <0.001* 2.6 ± 0 . 5 5.2 ± 1 . 4 <0.001* 
(mmol/1) — 一 
FPG 
5.1 ± 0 . 6 5.3 土 0.7 0.172 4.9 ± 0 . 5 5.1 ± 0 . 7 0.159 
(mmol/1) 
SBP (mmHg) 119 ± 1 0 129 ± 1 4 <0.001* 113 土 13 135 ± 1 9 <0.001* 
DBP(mmHg) 72 ± 8 79 土 7 <0.001* 66 土 9 74 土 13 <0.001* 
Data represent means 土 SD 
P values were calculated by the Student's t-test. * 0.05 
# As the Friedewald's formulae for calculating LDL-C are only valid for specimens 
in which TG < 4.5 mmol/L, only 23 male and 24 female FCH cases have valid 
LDL-C readings. 
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3.2.2 CH cases versus controls 
Comparisons of the characteristics between CH cases and controls were listed in 
the Table 6. CH cases were barely age-gender matched with controls (P=0.051) 
(Table 6). The reasons were explained above. Except HDL-C levels, all lipid levels 
(TC, TG, LDL-C) and other characteristics (BMI，FPG，SBP, DBP) of CH cases were 
significantly higher than these of controls (户<0.001) (Table 6). After analyzing the 
characteristics of different genders separately, the results showed that there were no 
gender related differences among these characteristics (Table 7). The results also 
indicated that obesity (high BMI), hyperglycemia (high FPG) and hypertension (high 
SBP, DBP) are the common metabolic abnormalities of CH. 
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Table 6. Characteristics of CH cases versus controls 
Trait Controls CH cases P value 
Number 176 115 NA 
M/F 61/115 53/62 0.051 
Age 50.1 土 9.4 52.6 ± 12.9 0.078 
BMI (kg/m^) 23.6 ± 3.3 26.0 ±3 .1 <0.001* 
TC (mmol/1) 4.5 土 0.5 7.6 ±1 .2 <0.001* 
TG (mmol/1) 0.9 土 0.4 4.2 ± 2 . 6 <0.001* 
HDL-C (mmol/1) 1.5 ±0 .3 1.1 ±0 .3 <0.001* 
LDL-C# (mmol/1) 2 .6±0 .5 5.1 ±1 .3 <0.001* 
FPG (mmol/1) 5.0 ±0 .5 5.4 ±0 .7 <0.001* 
SBP (mmHg) 115 ± 1 2 140 ± 2 0 <0.001* 
DBP(mmHg) 68 土 9 81 ± 1 3 <0.001* 
Data represent means 土 SD 
P values were calculated by the Student's t-test and Chi-square test. *P<0.05 
* As the Friedewald's formulae for calculating LDL-C are only valid for specimens 
in which TG < 4.5 mmol/L, only 86 out of 115 CH cases have valid LDL-C readings. 
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Table 7. The characteristics of CH cases versus controls in different genders 
Trait Males Females 
Controls CH cases Controls CH cases 
Number P value P value 
(n=61) (n=53) (n=115) (n=62) 
Age 52.4 ±10 .1 47.4 ±11 .5 0.016 48.9 ± 8.8 57.0 土 ] 2 . 5 <0.001 
BMI (kg/m-) 23.8 ± 3 . 2 26.4 ± 3 . 0 <0.001 23.5 ± 3 . 3 25.8 ±3 .1 <0.001 
TC (mmol/1) 4.6 ± 0 . 5 7 . 6 ± 1 . 2 <0.001 4.5 ± 0.5 7 . 6 ± 1 J <0.001 
TG (mmol/1) 1.0 ± 0 . 4 4.0 ± 2 . 3 <0.001 0.9 ± 0 . 3 4.4 ± 2 . 8 <0.001 
HDL-C 
1.4 土 0.3 1.1 土 0.3 <0.001 1.5 ± 0 . 4 1.2 土 0.3 <0.001 
(mmol/1) 
LDL-C # 
2.8 ± 0 . 5 5.2 土 1.5 <0.001 2.6 ± 0 . 5 5.0 ± 1 . 1 <0.001 
(mmol/1) 
FPG 
5.1 ± 0 . 6 5.4 ± 0 . 7 0.021 4.9 ± 0 . 5 5.4 土 0.8 <0.001 
(mmol/l) 一 一 
SBP (mmHg) 119 ± 1 0 136 ± 1 6 <0.001 113 ± 1 3 144 ± 2 2 <0.001 
DBP(mmHg) 72 ± 8 83 ± 12 <0.001 66 ± 9 78 ± 1 3 <0.001 
Data represent means 土 SD 
P values were calculated by the Student's t-test. * P< 0.05 
# As the Friedewald's formulae for calculating LDL-C are only valid for specimens 
in which TG < 4.5 mmol/L, only 40 male and 46 female FCH cases have valid 
LDL-C readings. 
3.3 Hardy-Weinberg equilibrium 
3.3.1 FCH cases and controls 
The Chi-square values of the Chi-square goodness-of-fil test to assess HWE of 
25 SNPs were listed (Table 8). Eight SNPs were eliminated because of different 
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reasons: no minor alleles (rs675, G360H, rs6656547), low call rates of the 
MassARRAY system (rs2072560, rs2073658) or not in HWE (rs320, rs327, rs297). 
Three SNPs (rs675, G360H, rs6656547) were proved to have no minor alleles in 
Chinese. Less than optimum polymerase chain reaction (PGR) condition or 
competitions among primers among multiplex condition might cause low call rates of 
the MassARRAY system. The genotyping errors or non-random mating might affect 
the study population violating the HWE. Seventeen SNPs (11 SNPs in 
APOA1/C3/A4/A5, two SNPs in USFl, one SNP in LPL, two SNPs in PPAR r , one 
SNP in ADD 1) were selected for further analysis (Table 8). 
3.3.2 CH cases and controls 
The Chi-square values of the Chi-square goodness-of-fit test to assess HWE of 
25 SNPs were listed (Table 9). Eleven SNPs were eliminated because of different 
reasons: no minor alleles (rs675, G360H, rs6656547V low call rates of the 
MassARRAY system (rs2072560, rs2Q73658) or not in HWE rrs5Q7Q. rs2075291, 
rs320, rs327, rs297, - 6 8 1 0 G ) . Fourteen SNPs (nine SNPs in APOA1/C3/A4/A5 
gene cluster, two SNPs in USFl, one SNP in LPL, one SNP in PPAR r , one SNP in 
A D D l ) were selected for further analysis (Table 9). 
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Table 8. Hardy-Weinberg equilibrium in FCH cases and controls 
P value 
SNP ID Gene 
Controls FCH case 
rs5070 APOAl 0.56 0.27 
rs4520 AP0C3 1.03 1.89 
rs5128 AP0C3 0.14 0.08 
rs2854116 AP0C3 0.24 0.04 
rs675 AP0A4 No minor alleles No minor alleles 
G360H AP0A4 No minor alleles No minor alleles 
rs6589567 APOA4-A5 0.92 0.74 
rs6589568 APOA4-A5 0.30 2.7] 
rs 1729410 APOA4-A5 3.54 0.02 
rs651821 AP0A5 0.29 0.01 
rs662799 AP0A5 0.19 0.00 
rs2072560 AP0A5 Low call rate Low call rate 
rs2075291 AP0A5 0.26 0.06 
rs2266788 AP0A5 0.26 0.49 
rs3737787 USFl 0.03 0.08 
rs2073658 USFl Low call rate Low call rate 
rs2774276 USFl 0.00 0.10 
rs6656547 USFl No minor alleles No minor alleles 
rs320 LPL 4.04 * 4.67 * 
S447X LPL 0.05 0.54 
rs327 LPL 4.42 * 4 .67* 
rs297 LPL 4.13 * 4.67 * 
161C>T PPARy 1.45 1.35 
- 6 8 I O G PPARy 0.70 0.74 
rs4961 A D D � 0.41 2.92 
P values were calculated by the Chi-square goodness-of-fit test with first degree of 
freedom. * l i y l > 3.84, not in HWE. 
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Table 9. Hardy-Weinberg equilibrium in CH cases and controls 
P value 
SNP ID Gene 
Controls CH case 
rs5070 APOAl 0.56 4.97 * 
rs4520 AP0C3 1.03 1.96 
rs5]28 AP0C3 0.14 0.55 
rs2854116 AP0C3 0.24 3.12 
rs675 AP0A4 No minor alleles No minor alleles 
G360H AP0A4 No minor alleles No minor alleles 
rs6589567 APOA4-A5 0.92 1.15 
rs6589568 APOA4-A5 0.30 2.43 
rs 1 7 2 9 4 1 0 A P O A 4 - A 5 3 .54 1.27 
i.s651821 AP0A5 0.29 0.20 
rs662799 AP0A5 0.19 0.13 
rs2072560 AP0A5 Low call rate Low call rate 
rs2075291 AP0A5 0.26 5.11 * 
rs2266788 AP0A5 0.26 0.07 
rs3737787 USFl 0.03 0.04 
rs2073658 USFl Low call rate Low call rate 
rs2774276 USFl 0.00 0.5] 
rs6656547 USFl No minor alleles No minor alleles 
rs320 LPL 4.04 * 3.25 
S447X LPL 0.05 0.84 
rs327 LPL 4.42 * 3.71 
rs297 LPL 4.13 * 2.21 
1 6 1 0 T PPARy 1.45 0.80 
- 6 8 1 0 G PPARy 0.70 4.93 * 
rs496� ADDl 0.41 2.19 
P values were calculated by the Chi-square goodness-of-fit test with first degree of 
freedom. * if 义2�3.84，not in HWE 
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3.4 APOA1/C3/A4/A5 gene cluster 
3.4.1 FCH cases versus controls 
3.4.1.1 Genotypic distribution and allelic frequency 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of 11 SNPs in HWE between FCH cases and 
controls (Table 10). To avoid the counts expected by the Chi-square test in any cells 
of rs5Q70. rs2Q75291. rs2266788 and rs6589567 less than five, their minor allele 
homozyotes were combined with heterozygotes. Both genotypic distribution and 
allelic frequency of seven SNPs (rs4520, rs6589567. rs6589568. rs651821. rs662799, 
1.S2075291, rs2266788) were significantly different between FCH cases and controls 
(P<0.05) (Table 10). Among them, the P values of four AP0A5 SNPs (rs651821, 
rs662799, rs2075291, rs2266788) were lower than the significance level adjusted 
with the Bonferroni's correction (P<0.003). Seven FCH associated SNPs were 
selected to do the further binary logistic regression test. 
56 
Table 10. Comparisons of genotypic distribution and allelic frequency of the SNPs 
in APOA1/C3/A4/A5 gene cluster between FCH cases and controls 
SNP Genotype Controls FCH cases P value 
rs5070 (APOAl) AA 90 (51.7) 36 (64.3) 
AG/GG 84 (48.3) 20 (35.7) 0.100 
Total 174 56 
A/G allele freq. 0.727/0.273 0.795/0.205 0.154 
rs4520 (AP0C3) TT 60 (34.1) 30 (53.6) 
CT 91 (51.7) 19(33.9) 
CC 25 (14.2) 7 (12.5) 0.029 
Total 176 56 
T/C allele fi-eq. 0.599/0.401 0.705/0.295 0.044 
rs5128(APOC3) CC 94 (54.7) 23 (41.1) 
CG 65 (37.8) 25 (44.6) 
GG 13(7.6) 8(14.3) 0.129 
Total \T2 56 
C/G allele freq, 0.735/0.265 0.634/0.366 0.040 
rs2854116 (APOC3) 丁丁 66 (38.6) 17(30.4) 
TC 78 (45.6) 27 (48.2) 
“ CC 27(15.8) 12(21.4) 0.444 
Total 171 56 
T/C allele freq. 0.614/0.386 0.545/0.455 0.194 
r s _ 1 0 C C 54 (30.9) 26 (46.4) 
(APOA4-A5) 
“ CG 97 (55.4) 24 (42.9) 
‘ GG 24(13.7) 6(10.7) 0.103 
Total 175 56 
C/G allele fieq. 0.586/0.414 0.679/0.321 0.080 
rs 娜 7 CC 106 (61.3) 24 (42 .9 ) 
(APOA4-A5) 
“ C A / A A 67 (38 .7) 32 (57 .1 ) 0 . 0 1 6 
Total 173 56 
C/A allele freq. 0.775/0.225 0.634/0.366 0.003 
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continue 
SNP Genotype Controls FCH cases P value 
rs6589568 
AA 90 (51.4) 23 (41.1) 
(APOA4-A5) 
^ 73 (41.7) 21 (37.5) 
GG 12(6.9) 12 (21.4) 0.008 
Total 175 56 
A/G allele freq. 0.723/0.277 0.598/0.402 0.013 
rs651821 (AP0A5) 丁丁 102 (59.0) 9 (16.3) 
CT 60 (34.7) 26 (47.3) 一 
CC 11 (6.4) 20 (36.4) <0.001 * 
Total 173 55 
T/C allele freq. 0.763/0.237 0.400/0.600 <0.001 * 
rs662799 (AP0A5) AA 101(58.4) 9(16.1) 
AG 6�（35.3) 27 (48.2) 
GG 11 (6.4) 20 (35.7) <0.001 * 
Total 173 56 
A/G allele freq. 0.760/0.240 0.402/0.598 <0.001 * 
rs2075291 (AP0A5) CC 160(92) 40 (72.7) 
CAMA 15(27.3) <0.001 * 
Total 173 55 
C/A allele freq. 0.962/0.038 0.855/0.145 <0.001* 
rs2266788 (AP0A5) AA 119 (67.6) 17 (30.4) 
AG/GG 57 (32.4) 39 (69.6) <0.001 * 
Total 176 56 
A/G allele freq. 0.813/0.187 0.571/0.429 <0.001 * 
The numbers in ( ) represent the percentages. 
P values were calculated by the Chi-square test. 
* P values were lower than the significance level adjusted with the Bonferroni's correction 
(P<0.003). 
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3.4.1.2 Odds ratio 
The binary logistic regression test was used to determine the risk of developing 
FCH among different genotypes adjusted for age, gender and BMI. The OR of the 
heterozygotes of rs4520 in AP0C3 was significantly lower than that of major allele 
homozygotes (OR=0.4，户=0.004) (Table 11). Six SNPs (rs6589567, rs6589568, 
rs651821, rs662799, rs2075291, rs2266788) were found to have FCH risk 
genotypes with significant higher ORs compared with the reference genotypes 
(95% CI, P<0.05) (Table 11). The odds ratios of the minor allele homozygotes of 
rs651821 and rs662799 in AP0A5 were 24.4 (8.4，70.9) and 24.6 (8.4, 72.0) 
respectively. Odds ratios of the minor allele earners of rs2075291 and rs2266788 in 
A P 0 A 5 were 4.4 (1.9, 10.4) and 6.2 (3.0, 12.6) respectively. Their P values were 
lower than the significance level adjusted with the Bonferroni's correction {P < 
0.003) (Table 11). Six SNPs with FCH risk genotypes were selected for further 
ANCOVA analysis. 
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Table 11. Relative risk of FCH according to different SNP genotypes in 
APOAl/C3/A4/A5 gene cluster 




CT 0.4 (0.2,0.7) 0.004 




CA/AA 2.2(1.2,4.1) 0.016 
rs6589568 ” ‘ 
AA 1.0 
(APOA4-A5) 
AG 1.1 (0.6,2.2) 0.720 




TC 6.1 (2.6，14.6) <0.001 * 




AG 6.2 (2.6, 14.8) <0.001* 








AG/GG 6.2 (3.0, 12.6) <0.001 * 
P values were calculated by the binary logistic regression test adjusted for age, 
gender and BMI. * P values were lower than the significance level adjusted with 
the Bonferroni's correction {P < 0.003). 
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3.4.1.3 Parameter analysis 
ANCOVA was used to compare the means of different parameters including lipid 
levels (TC, TG, LDL-C, HDL-C), FPG levels, SBP and DBP among different 
genotypes adjusted for age, gender and BMI (Table 12-17). The minor allele carriers 
of rs2266788 had lower HDL-C levels in controls compared with the major allele 
homozygotes (P=0.022) (Table 16). The minor allele carriers of rs2Q75291 had lower 
HDL-C levels in FCH cases (P=0.026), and lower SBP, DBP readings in controls 
(P=0.015 and 0.016 respectively) (Table 17). All their P values were higher than the 
significance level adjusted with the Bonferroni's correction (P�0 .003) . 
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Table 12. Parameter analysis of FCH cases and controls according to different 









CC 6.98 1.48 24 0.309 CC 4.48 0.47 105 0.420 
CA/AA 7.38 1.62 32 CA/AA 4.53 0.48 66 
TG (mmol/L) 
CC 3.20 2.36 24 0.454 CC 0.90 0.39 105 0.197 
CA/AA 3.67 2.64 32 CA/AA 0.94 0.36 66 
HDL-C 
CC 1.18 0.38 24 0.505 CC 1.49 0.33 105 0.221 
(mmol/L) 
CA/AA 1.12 0.33 32 CA/AA 1.45 0.37 66 
LDL-C 
CC 4.56 � . 7 7 20 0.151 CC 2.60 0.50 105 0.340 
(mmol/L) 
CA/AA 5.17 1.63 27 CA/AA 2.65 0.54 66 
Total 47 Total n i 
FBG (mmol/L) CC 5.29 0.81 24 0.402 CC 4.97 0.57 105 0.508 
CA/AA 5.16 0.64 32 CA/AA 5.00 0.44 66 
SBP (mniHg) CC 129.47 18.22 24 0.229 CC 114.64 13.18 105 0.297 
CA/AA 134.26 15.86 32 CA/AA 115.94 10.80 66 
DBP(mmHg) CC 73.67 10.74 24 0.090 CC 68.07 9.33 105 0.495 
CA/AA 78.78 10.75 32 CA/AA 68.37 8.99 66 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
rs6589567 (APOA4-A5) genotypes 
FCH cases Controls 
Parameters (n= 56) Mean SD N P value (n=173) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) AA 6.99 1.51 23 0.564 AA 4.46 0.49 89 0.425 
AG 7.29 1.70 21 AG 4.54 0.45 73 
GG 7 . 5 � 1.44 � 2 GG 4.58 0.42 11 
TG (mmol/L) AA 3.24 2.41 23 0.892 AA 0.87 0.37 89 0.155 
AG 3.52 2.06 2 丨 AG 0.95 0.35 73 
GG 3.82 3.46 12 GG 0.95 0.50 11 
HDL-C 
AA 1.17 0.39 23 0.745 AA 1.49 0.34 89 0.496 
(mmol/L) 
AG 1.10 0.36 21 AG 1.45 0.37 73 
GG 1.17 0.27 丨 2 GG 1.44 0.32 11 
LDL-C 
AA 4.56 1.82 19 0.173 AA 2.58 0.51 89 0.462 
(mmol/L) 
AG 4.99 1.84 18 AG 2.65 0.5 丨 73 
GG 5.43 1.10 10 GG 2.72 0.55 11 
Total 47 Total 173 
FPG (mmol/L) AA 5.30 0.83 23 0.386 AA 4.90 0.54 89 0.016 * 
AG 5.04 0.63 21 AG 5.10 0.49 73 
GG 5.37 0.61 12 GG 4.85 0.53 11 
SBP (mmHg) AA 128.28 17.64 23 0.277 AA 115.08 12.88 89 0.526 
AG 133.06 15.59 21 AG 116.11 12.18 73 
GG 138.25 17.16 12 GG 113.58 8.99 11 
DBP (mmHg) AA 73.96 10.88 23 0.335 AA 68.13 9.41 89 0.945 
AG 77.71 9.80 21 AG 68.32 9.11 73 
GG 79.67 丨 2.67 12 GG 68.76 8.59 11 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
*户 < 0 . 0 5 
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Table 12. Parameter analysis of FCH cases and controls according to different 
r s 6 5 8 9 5 6 7 (APOA4-A5) genotypes 
FCH cases Controls 
Parameters (n= 55) Mean SD N P value (n=171) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) C C 7.30 1.62 20 0.486 CC 4.65 0.30 11 0.085 
C T 6.97 1.65 26 CT 4.38 0.54 58 
T T 7.64 1.18 9 TT 4.55 0.43 102 
TG(mniol/L)# C C 0.54 0.35 20 0.121 CC 0.91 0.43 11 0.594 
C T 0.42 0.22 26 CT 0.92 0.37 58 
T T 0.32 0.35 9 TT 0.91 0.38 102 
HDL-C 
C C 1.13 0.34 20 0.484 CC 1.46 0.33 11 0.060 
(mmol/L) 
C T 1.16 0.39 26 CT 1.42 0.39 58 
T T 1.12 0.31 9 TT 1.49 0.32 102 
LDL-C 
C C 5.27 1.71 14 0.570 CC 2.81 0.41 11 0.288 
(mmo/L) 
C T 4.53 1.80 24 C T 2.55 0.58 58 
T T 5.31 1.34 8 丁丁 2.65 0.48 102 
Total 46 Total � 7 1 
FBG (mmol/L) C C 5.13 0.56 20 0.627 CC 5.10 0.40 11 0.718 
C T 5.34 0.77 26 CT 4.95 0.44 58 
T T 5.04 0.89 9 TT 4.99 0.58 102 
SBP (mmHg) C C 131.77 17.79 20 0.527 CC 116.64 12.74 11 0.492 
C T 136.82 14.39 26 CT 113.03 11.80 58 
丁丁 121.67 18.52 9 TT 116.27 12.57 102 
DBP (mmHg) C C 76.82 11.72 20 0.115 CC 66.12 11.20 11 0.626 
C T 78.54 9.89 26 CT 67.56 8.29 58 
T T 71.63 11.73 9 TT 68.71 9.32 102 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
# The TG levels of FCH cases were log-transformed. 
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Table 12. Parameter analysis of FCH cases and controls according to different 








TC (inmol/L) AA 7.64 1.18 9 0.546 AA 4.55 0.43 101 0.072 
GG 7.30 1.62 20 GG 4.65 0.30 11 
GA 7.00 1.63 27 GA 4.38 0.54 59 
TG(mmol/L)# AA 0.32 0.35 9 0.119 AA 0.91 0.38 101 0.699 
GG 0.54 0.35 20 GG 0.91 0.43 11 
GA 0.41 0.22 27 GA 0.92 0.37 59 
HDL-C 
AA 1.12 0.31 9 0.551 AA 1.49 0.32 101 0.079 
(mmol/L) 
GG 1.13 0.34 20 GG 1.46 0.33 11 
GA 1.17 0.38 27 GA 1.42 0.38 59 
LDL-C 
AA 5.31 1.34 8 0.515 AA 2.66 0.48 101 0.262 
(mmo/L) 
GG 5.27 1.71 14 GG 2.8 丨 0 . 4 � 11 
GA 4.58 1.79 25 GA 2.54 0.57 59 
Total 47 Total 17] 
FBG (mniol/L) AA 5.04 0.89 9 0.619 AA 4.98 0.58 101 0.716 
GG 5.13 0.56 20 GG 5.10 0.40 11 
GA 5.34 0.75 27 GA 4.96 0.44 59 
SBP(mmHg) AA 121.67 18.52 9 0.596 AA 116.24 12.63 101 0.531 
GG 131.77 17.79 20 GG 116.64 12.74 11 
GA 136.05 14.67 27 GA 113.14 11,72 59 
DBP (mniHg) AA 71.63 11.73 9 0.177 AA 68.61 9.31 101 0.652 
GG 76.82 11.72 20 GG 66.12 11.20 11 
GA 78.07 10.00 27 GA 67.75 8.35 59 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
#The TG levels of FCH cases were log-transformed. 
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Table 16. Parameter analysis of FCH cases and controls according to different 
rs2266788 (AP0A5) genotypes 
FCH cases Controls 
Parameters (n= 56) Mean SD N P value (n=174) Mean SD N P value 
Genotype Genotype 
T C ( m m o l / L ) 
AA 7.01 1.61 17 0.504 AA 4.53 0.45 118 0.375 
AG/GG 7.30 1.55 39 AG/GG 4.44 0.51 56 
T G ( m m o l / L ) 
AA 3.62 2.56 17 0.992 AA 0.92 0.39 118 0.518 
AG/GG 3.40 2.52 39 AG/GG 0.90 0.36 56 
H D L - C 
AA 1.07 0.27 17 0.754 AA 1.48 0.34 118 0.022* 
(mmol/L) 
AG/GG 丨.18 0.38 39 AG/GG 1.44 0.37 56 
L D L - C 
AA 4.59 1.98 13 0.282 AA 2.63 0.49 118 0.770 
(mmol/L) 
AG/GG 5.03 1.60 34 AG/GG 2.60 0.55 56 
Total 47 Total 174 
FBG (mmol/L) AA 5.33 0.91 17 0.296 AA 4.99 0.56 118 0.778 
AG/GG 5.17 0.61 39 AG/GG 4.97 0.44 56 
SBP (mmHg) AA 129.86 18.53 17 0.732 AA 115.92 12.53 118 0.897 
AG/GG 133.23 16.32 39 AG/GG 114.11 11.97 56 
DBP (mmHg) AA 73.00 9.52 17 0.056 AA 68.26 9.50 118 0.788 
AG/GG 78.15 11.27 39 AG/GG 68.22 8.47 56 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
*尸 < 0 . 0 5 
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Table 17. Parameter analysis of FCH cases and controls according to different 









CC 7.37 1.39 40 0.479 CC 4.51 0.47 158 0.381 
CA/AA 7.13 1.54 15 CA/AA 4.38 0.51 13 
TG (mmol/L) 
CC 3.15 2.41 40 0.316 CC 0.90 0.37 158 0.271 
CA/AA 4.27 2.75 15 CA/AA 1.05 0.46 13 
HDL-C 
C C 1.20 0.38 40 0.026* CC 1.48 0.34 158 0.379 
(mmol/L) 
CA/AA 1.02 0.23 15 CA/AA 1.36 0.44 13 
LDL-C 
C C 5.03 1.44 36 0.799 CC 2.62 0.51 158 0.861 
(mmol/L) 
CA/AA 5.03 1.80 10 CA/AA 2.57 0.60 13 
Total 46 Total 171 
FBG (mmol/L) CC 5.15 0.68 40 0.425 CC 4.98 0.53 158 0.747 
CA/AA 5.30 0.76 15 CA/AA 4.93 0.46 13 
SBP (mniHg) C C 131.35 16.97 40 0.780 CC 115.70 12.27 158 0.015* 
CA/AA 133.18 17.09 15 CA/AA 108.38 10.84 13 
DBP (mmHg) C C 76.37 11.42 40 0.856 CC 68.72 8.91 158 0.016* 
CA/AA 76.76 10.20 15 CA/AA 61.72 10.20 13 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
* P < 0 . 0 5 
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3.4.1.4 Haplotype analysis 
Haploview (Daly Lab.) was used to do the haplotype case-control association 
tests. According to the default setting of the Haploview, three haplotype blocks were 
found. The first haplotype block consisted of two AP0C3 SNPs (rs4520, rs5128) in 
strong LD (Table 18). The P value of the haplotype carrying the minor allele of 
rs4520 was lower than the significance level of 0.05 (P=0.0186). The second 
haplotype consisted of two APOA4-A5 SNPs (rs6589567. rs6589568) (Table 19). 
The haplotype carrying the minor alleles of both SNPs was significantly associated 
with FCH (P=0.003) (Table 19). The third haplotype block consisted of three AP0A5 
SNPs (rs2075291，rs651821. rs662799) (Table 20). Two haplotypes carrying the 
minor alleles of rs651821 and rs662799 were significantly associated with FCH 
(P<0.001) (Table 20). 
Table 18. FCH case-control association test of the haplotypes in AP0C3 
FCH cases/Control FCH cases /Control 
Haplotypes Chi square P value 
counts ratios 
rs4520 rs5128 
1 I 40.2 118.5 0.359 0.337 0.185 0.6669 
2 � 30.8 140.2 0.275 0.398 5.534 0.0186* 
� 2 38.8 92.5 0.347 0.263 2.939 0.0865 
P values were calculated by the Chi-square test. 
Major alleles of each SNP are represented as 1 and minor alleles are represented as 2. 
value was lower than the significance level of 0.05 (P<0.05). 
The LD of the SNPs is L 0 D ^ 2 and D'=l. 
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Table � 9 . FCH case-control association test of the haplotypes in APOA4-A5 
FCH case/Control FCH case /Control 
Haplotypes Chi square P value 
counts ratios 
rs6589567 rs6589568 
1 1 67.0 254.9 0.598 0.724 6.333 0.012* 
2 2 40.8 78.8 0.365 0.224 8.785 0.003* 
1 2 4.2 18.3 0.037 0.052 0.406 0.524 
P values were calculated by the Chi-square test. 
* P values were lower than the significance level adjusted with the Bonferroni's correction {P < 
0.017). Major alleles of each SNP are represented as 1 and minor alleles are represented as 2. 
The LD of the SNPs is L 0 D ^ 2 and D’=l. 
Table 20. FCH case-control association test of the haplotypes in AP0A5 
FCH case/Control FCH case /Control , 
Haplotypes Chi square P value 
counts ratios 
rs2075291 rs65]821 rs662799 
1 1 1 45.0 266.6 0.402 0.757 48.666 <0.001* 
1 2 2 50.8 71.4 0.454 0.203 27.526 <0.001* 
2 2 2 16.2 13.0 0.145 0.037 16.7 <0.001* 
P values were calculated by the Chi-square test. 
*P values were lower than the significance level adjusted with the Bonferroni's correction {P < 0.017). 
Major alleles of each SNP are represented as 1 and minor alleles are represented as 2. 
The LD of the SNPs is L 0 D ^ 2 and D '=l . 
3.4.2 CH cases versus controls 
3.4.2.1 Genotypic distribution and allelic frequency 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of nine SNPs (rs452Q, rs5128, rs2854116, 
rsl729410, rs6589567, rs6589568. rs65182L rs662799, rs2266788) in HWE 
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between CH cases and controls (Table 21). Both genotypic distribution and allelic 
frequency of the SNPs were significantly different between CH cases and controls 
(户<0.05). Among them, the P values of five SNPs (rs4520. rs6589567, rs651821, 
rs662799, r s2266788�were lower than the significance level adjusted with the 
Bonferroni's correction (户<0.004). Nine SNPs associated with CH were selected to 
do the further binary logistic regression test. 
3.4.2.2 Odds ratio 
The binary logistic regression test was used to determine the risk of developing 
CH among different genotypes adjusted for age, gender and BMI. The ORs of the 
minor allele carriers of rs4520 and rs 1729410 were significantly lower than that of 
the major allele homozygotes (OR=0.4, 0.2 respectively, P<0.05) (Table 22). Seven 
SNPs (rs5128, rs2854116. rs6589567, rs6589568. rs65182L rs662799, rs2266788) 
were found to have CH risk genotypes with significant higher ORs compared with 
the reference genotypes (95% CI, P<0.05) (Table 22). The odds ratios of the minor 
allele homozygotes of rs651821 and rs662799 in AP0A5 compared with the 
reference genotypes were 17.0 (6.9，42.3) and 16.8 (6.8，41.8) respectively. The P 
values of all three AP0A5 SNPs were lower than the significance level adjusted with 
the Bonferroni's correction (P < 0.004) (Table 22). Eight SNPs with FCH risk 
genotypes were selected for further ANCOVA analysis. 
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Table 21. Comparisons of genotypic distribution and allelic frequency of the SNPs in 
APOAl/C3/A4/A5 gene cluster between CH cases and controls 
SNP Genotype Controls CH cases P value 
rs4520 (AP0C3) 丁丁 60 (34.]) 62 (54.4) 
CT 91 (51.7) 40 (35.1) 
CC 25 (14.2) 12 (10.5) 0.003 * 
Total 176 114 
T/C allele 
0.599/0.401 0.719/0.281 0.003 * 
fi-equencies 
rs5128(APOC3) CC 94 (54.7) 44 (38.9) 
CG 65 (37.8) 50 (44.2) 
GG 13(7.6) 19(16.8) 0.009 
Total 172 113 
C/G allele 
0.736/0.264 0.61 1/0.389 0.002 * 
fi-equencies 
rs2854116 (APOC3) TT 66 (38.6) 32 (27.8) 
TC 78 (45.6) 48 (41.7) 
CC 27 (15.8) 35 (30,4) 0.009 
Total 171 n 5 
T/C allele ^ … ^ 
0.614/0.386 0.487/0.513 0.003 * 
frequencies 
rsl729410(APOA4-A5) CC 54 (30.9) 56 (48.7) 
CG 97 (55.4) 52 (45.2) 
GG 24 (13.7) 7 (6.1) 0.004 
Total 175 115 
C/G allele 
0.586/0.414 0.713/0.287 0.002 * 
frequencies 
rs6589567 (APOA4-A5) CC 106 (61.3) 49 (42.6) 
CA 56 (32.4) 48 (41.7) 
AA 11 (6.4) 18 (15.7) 0.002 * 
Total 173 115 
C/A allele 




SNP Genotype Controls CH cases P value 
rs6589568 (APOA4-A5) AA 90 (51.4) 46 (40) 
AG 73 (41.7) 47 (40.9) 
GG 12(6.9) 22 (19.1) 0.004 
Total 175 115 
A/G allele 
0.723/0.277 0.604/0.396 0.003 * 
frequencies 
rs651821 (AP0A5) 丁丁 102 (59.0) 21 (18.3) 
CT 60 (34.7) 59 (51.3) 
CC 11 (6.4) 35 (30.4) <0.001 * 
Total 173 115 
T/C allele 
0.763/0.237 0.439/0.561 < 0 . 0 0 � * 
frequencies 
rs662799 (AP0A5) AA 101 (58.4) 21(18.4) 
AG 61 (35.3) 58 (50.9) 
GG 11 (6.4) 35 (30.7) <0.001 * 
Total 173 114 
A/G allele 
0 . 7 6 0 / 0 . 2 4 0 0 . 4 3 9 / 0 . 5 6 1 < 0 . 0 0 1 * 
frequencies 
rs2266788 (AP0A5) AA 119 (67.6) 47 (40.9) 
A G 4 8 (27 .3) 5 2 ( 4 5 . 2 ) 
G G 9 ( 5 . 1 ) 1 6 ( 1 3 . 9 ) < 0 . 0 0 1 * 
Total 176 m 
A/G allele freq. 0 . 8 1 3 / 0 . 1 8 7 0 . 6 3 5 / 0 . 3 6 5 < 0 . 0 0 1 * 
The numbers in ( ) represent the percentages. 
P values were calculated by the Chi-square test. 
* P values were lower than the significance level adjusted with the Bonferroni's correction 
CP<0.004). 
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Table 22. Relative risk of CH according to different SNP genotypes in APOA1/C3/A4/A5 gene cluster 
SNP Genotype Odds ratio (95% CI) P value 
rs4520 (AP0C3) TT 1.0 
CT 0.4 (0.2,0.7) 0.002 * 
CC 0.4 (0.2, ].0) 0.062 
rs5]28 (AP0C3) CC 1.0 
CG 1.9(1.1,3.4) 0.023 
GG 3.8 (1.6,9.0) 0.003 * 
rs2854116 (APOC3) TT 1.0 
CT 1.1 (0.6,2.1) 0.670 
CC 3.0 (1.5,8.6) 0.003 * 1 
j 
rsl729410(APOA4-A5) CC 1.0 
CG 0.5 (0.3,0.9) 0.022 
GG 0.2 (0.1,0.7) 0.005 
rs6589567 (APOA4-A5) CC 1.0 
CA 1.9 (1.1,3.3) 0.025 
AA 3.5(1.4,8.6) 0.007 
rs6589568 (APOA4-A5) AA 1.0 
AG 1.3 (0.8’ 2.3) 0.347 
GG 3.5(1.5,8.3) 0.005 
rs651821 (AP0A5) TT 1.0 
TC 6.7 (3.4, 13.2) <0.001 * 
CC 17.0 (6.9，42.3) <0.001 * 
rs662799 (AP0A5) AA 1.0 
AG 6.4 (3.3,12.6) <0.001 * 
GG 16.8 (6.8’ 41.8) <0.001* 
rs2266788 (AP0A5) AA I.O 
AG 3.8 (2.1,6.9) <0.001* 
GG 5.3 (2.0, 14.1) 0.001 * 
P values were calculated by the binary logistic regression test adjusted for age, gender and BMI. * P 
values were lower than the significance level adjusted with the Bonferroni's correction {P < 0.004). 
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3.4.2.3 Parameter analysis 
ANCOVA was used to compare the means of different parameters including lipid 
levels (TC, TG, LDL-C, HDL-C), FPG levels, SBP and DBP among different 
genotypes adjusted for age, gender and BMI (Table 23-30). The minor allele 
homozygotes of rs651821 in AP0A5 had higher log-transformed TG levels in CH 
cases compared with the major allele homozygotes (?=0.024) (Table 28). The minor 
allele homozygotes of rs662799 in AP0A5 also had higher log-transformed TG 
levels in CH cases compared with the major allele homozygotes (户=0.010) (Table 
29). All their P values were higher than the significance level adjusted with the 
Bonferroni's correction (户〉0.004). 
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Table 12. Parameter analysis of FCH cases and controls according to different 
r s 6 5 8 9 5 6 7 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=l 13) Mean SD N P value (n=170) Mean SD N F value 
Genotype Genotype 
TC (mmol/L) CC 7.45 1.00 44 0.502 CC 4.50 0.47 92 0.129 
CG 7.72 1.27 50 CG 4.44 0.50 65 
GG 7.75 1.41 19 GG 4.72 0.24 13 
TG (mmol/L)# CC 0.56 0.20 44 0.298 CC 0.89 0.38 92 0.085 
CG 0.54 0.18 50 CG 0.95 0.39 65 
GG 0.63 0.28 19 GG 0.97 0.38 13 
HDL-C 
CC 1.04 0.22 44 0.038* CC 1.44 0.34 92 0.881 
(mmol/L) 
CG 1.21 0.33 50 CG 1.50 0.36 65 
GG 1.13 0.20 19 GG 1.48 0.33 13 
LDL-C 
CC 5.10 1.15 33 0.982 CC 2.67 0.46 92 0.133 
(mniol/L) 
CG 5.12 1.34 40 CG 2.51 0.57 65 
GG 5.21 丨.79 12 GG 2.82 0.42 13 
Total 85 Total 170 
FBG (mmol/L) CC 5.47 0.72 44 0.338 CC 4.98 0.56 92 0.771 
CG 5.28 0.80 50 CG 5.00 0.46 65 
GG 5.48 0.56 19 GG 4.98 0.34 13 
SBP (mmHg) CC 140.01 19.52 44 0.784 CC 115.61 12.25 92 0.544 
CG 140.99 20.89 50 CG 115.51 12.55 65 
GG 137.96 14.98 19 GG 111.18 12.25 13 
DBP (mmHg) CC 81.83 13.13 44 0.765 CC 68.39 9.34 92 0.865 
CG 78.87 12.59 50 CG 67.85 8.91 65 
GG 80.95 11.22 19 GG 66.18 8.35 13 
P values were calculated by ANCOVA adjusted for age, gender and BMI, 
< 0.05, # The TG levels of CH cases were log-transformed. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
r s6589567 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=l 15) Mean SD N P value (n=169) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) CC 7.57 1.22 35 0.872 CC 4.50 0.43 27 0.956 
CT 7.69 丨.33 48 CT 4.50 0.47 76 
TT 7.53 0.93 32 丁丁 4.48 0.49 66 
TG (nimoI/L) CC 4.78 3.18 35 0.470 CC 0.87 0.33 27 0.661 
CT 3.84 2.14 48 CT 0.96 0.39 76 
TT 4.23 2.31 32 TT 0.88 0.38 66 
HDL-C 
CC 1.16 0.26 35 0.118 CC 1.54 0.32 27 0.657 
(mmol/L) 
CT 1.17 0.32 48 CT 1.45 0.36 76 
TT 丨.04 0.22 32 TT 丨.44 0.35 66 
LDL-C 
CC 5.00 1.43 23 0.867 CC 2.57 0.54 27 0.929 
(mmol/L) 
CT 5.21 1.40 39 CT 2.62 0.54 76 
丁丁 5.09 1.11 24 TT 2.65 0.48 66 
Total 86 Total 169 
FBG (mmoI/L) CC 5.31 0.54 35 0.323 CC 4.99 0.55 27 0.369 
CT 5.34 0.85 48 CT 4.94 0.51 76 
丁丁 5.57 0.72 32 TT 5.04 0.53 66 
SBP (mmHg) CC 141.26 16.91 35 0.535 CC 111.85 12.38 27 0.505 
CT 139.70 18.86 48 CT 116.11 11.67 76 
丁丁 139.32 22.30 32 TT 115.19 13.06 66 
DBP (mmHg) CC 82.32 11.56 35 0.523 CC 68.40 9.23 27 0.623 
CT 78.78 11.64 48 CT 67.44 8.31 76 
T T 81.14 14.72 32 TT 68.86 9.87 66 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
rs6589567 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=I 15) Mean SD N 户 value (n=173) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) CC 7.53 1.18 56 0.797 CC 4.44 0.51 52 0.276 
CG 7.68 1.24 52 CG 4.55 0.46 97 
GG 7.69 0.92 7 GG 4.44 0.39 24 
TG (mmol/L)# CC 0.62 0.22 56 0.065 CC 0.93 0.36 52 0.324 
CG 0.52 0.19 52 CG 0.91 0.38 97 
GG 0.57 0.14 7 GG 0.85 0.36 24 
HDL-C 
CC 1.10 0.25 56 0.281 CC 1.45 0.37 52 0.638 
(mmol/L) 
CG 1.17 0.31 52 CG 1.48 0.33 97 
GG 1.05 0.27 7 GG 1.49 0.36 24 
LDL-C 
CC 5.09 1.40 37 0.994 CC 2.58 0.52 52 0.441 
(mmol/L) 
CG 5.15 1.28 43 CG 2.66 0.53 97 
GG 5.08 1.25 6 GG 2.56 0.39 24 
Total 86 Total 173 
FBG (mmol/L) CC 5.45 0.70 56 0.345 CC 4.94 0.47 52 0.726 
CG 5.30 0.77 52 CG 4.99 0.54 97 
GG 5.64 0.76 7 GG 5.04 0.59 24 
SBP (mmHg) CC 143.04 18.55 56 0.330 CC 114.92 12.29 52 0.878 
CG 137.33 20.47 52 CG 115.47 12.29 97 
GG 136.62 10.53 7 GG 116.29 13.11 24 
DBP (mmHg) CC 80.66 12.29 56 0.463 CC 67.35 10.28 52 0.605 
CG 79.51 13.06 52 CG 68.83 8.90 97 
GG 86.81 9.60 7 GG 67.85 7.91 24 
P values were calculated by ANCOVA, adjusted for age，gender and BMI. 
# The TG levels of CH cases are log-transformed. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
rs6589567 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=l 15) Mean SD N P value (n=17】） Mean SD N P value 
Genotype Genotype 
TC (mmol/L) AA 7.36 1.07 18 0.602 AA 4.59 0.44 10 0.708 
CC 7.68 1.21 49 CC 4.48 0.47 105 
CA 7.63 丨.22 48 CA 4.52 0.49 56 
TG (mmol/L) AA 4.28 3.18 18 0.820 AA 0.97 0.52 10 0.407 
C C 4.36 2.59 49 CC 0.90 0.39 105 
CA 4.09 2.29 48 CA 0.94 0.33 56 
H D L - C 
AA 1.15 0.30 18 0.753 AA 1.42 0.32 10 0.440 
(mmol/L) 
CC 丨.10 0.25 49 CC 丨.49 0.33 105 
CA 丨.15 0.30 48 CA 丨.46 0.38 56 
LDL-C 
AA 4.92 1.23 14 0.397 AA 2.74 0.58 10 0.811 
(mmol/L) 
CC 5.35 1.39 34 CC 2.60 0.50 105 
CA 4.99 1,29 38 CA 2.63 0.53 56 
Total 86 Total 1 7 1 
FBG (mmol/L) AA 5.31 0.62 18 0.708 AA 4.82 0.55 10 0.207 
CC 5.36 0.82 49 CC 4.97 0.57 105 
CA 5.46 0.68 48 CA 5.03 0.42 56 
SBP (mmHg) AA 135.69 14.38 18 0.102 AA 114.13 9.28 10 0.347 
CC 137.20 18.53 49 CC 114.64 13.18 105 
CA 144.64 20.73 48 CA � 1 6 . 2 6 11.09 56 
DBP (mmHg) AA 79.33 12.89 18 0.469 AA 69.23 8.90 10 0.766 
CC 79.53 12.30 49 CC 68.07 9.33 105 
CA 81.96 12.75 48 CA 68.22 9.08 56 
P values were calculated by ANCOVA, adjusted for age, gender and BMI. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
rs6589567 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=l 15) Mean SD N P value (n=173) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) AA 7.67 1.18 46 0.579 AA 4.46 0.49 89 0.425 
AG 7.67 1.26 47 AG 4.54 0.45 73 
GG 7.35 1.08 22 GG 4.58 0.42 11 
TG (mmol/L) AA 4.45 2.65 46 0.633 AA 0.87 0.37 89 0.155 
AG 4.09 2.31 47 AG 0.95 0.35 73 
GG 4.10 2.91 22 GG 0.95 0.50 11 
HDL - C 
AA 1.10 0.25 46 0.733 AA 1.49 0.34 89 0.496 
(nimoI/L) 
A G 1.14 0.31 47 AG 1.45 0.37 73 
GG 1.17 0.28 22 GG 1.44 0.32 11 
LDL-C 
AA 5.33 1.36 31 0.534 AA 2.58 0.51 89 0.462 
(mmol/L) 
AG 5.07 丨.37 37 AG 2.65 0.51 73 
GG 4.87 丨.17 18 GG 2.72 0.55 11 
Total 86 Total 173 
FBG (mmol/L) AA 5.38 0.84 46 0.956 AA 4.90 0.54 89 0.016* 
AG 5.42 0.68 47 AG 5.10 0.49 73 
GG 5.38 0.61 22 GG 4.85 0.53 11 
SBP (inniHg) AA 137.96 17.95 46 0.270 AA 115.08 12.88 89 0.526 
AG 143.31 22.09 47 AG 116.11 12.18 73 
GG 137.56 14.05 22 GG 113.58 8.99 11 
DBF (niniHg) AA 80.46 12.11 46 0.940 AA 68.13 9.41 89 0.945 
AG 80.83 13.09 47 AG 68.32 9.11 73 
GG 79.95 12.74 22 GG 68.76 8.59 11 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
*户 < 0 . 0 5 
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Table 12. Parameter analysis of FCH cases and controls according to different 
r s 6 5 8 9 5 6 7 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=l 13) Mean SD N P value (n=171) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) CC 7.63 l . I l 35 0.917 CC 4.65 0.30 � 1 0.085 
CT 7.58 1.13 59 CT 4.38 0.54 58 
TT 7.67 1.52 21 TT 4.55 0.43 102 
TG (mmol/L)# CC 0.65 0.25 35 0.024* CC 0.91 0.43 11 0.594 
C T 0.53 0.18 59 CT 0.92 0.37 58 
TT 0.55 0.17 21 TT 0.91 0.38 102 
HDL-C 
CC 1.14 0.33 35 0.950 CC 1.46 0.33 11 0.060 
(mmol/L) 
C T 1.12 0.26 59 CT 1.42 0.39 58 
丁丁 1.14 0.26 21 丁丁 1.49 0.32 102 
LDL-C 
CC 5.08 1.47 21 0.968 CC 2.81 0.41 11 0.288 
(mmol/L) 
C T 5.12 1.17 47 CT 2.55 0.58 58 i 
T T 5.17 1.58 18 丁丁 2.65 0.48 102 
1 T ^ 86 Total 171 
FBG (mmol/L) CC 5.46 0.73 35 0.160 CC 5.10 0.40 11 0.718 
C T 5.28 0.75 59 CT 4.95 0.44 58 
「 丁丁 5.60 0.64 21 TT 4.99 0.58 102 
SBP (mmHg) C C 142.70 16.54 35 0.543 CC 116.64 12.74 11 0.492 
C T 137.96 19.41 59 CT 113.03 11.80 58 
T T 141.62 22.62 21 TT 116.27 12.57 102 
DBP (mmHg) C C 81.13 12.02 35 0.722 CC 66.12 11.20 11 0.626 
I C T 79.60 13.57 59 CT 67.56 8.29 58 
j I 丁丁 82.03 10.49 21 TT 68.71 ,9.32 102 
P values were calculated by ANCOVA adjusted for age，gender and BMI. 
*尸 < 0.05, # The TG levels of CH cases were log-transformed. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
rs6589567 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=113) Mean SD N P value (n=171) Mean SD N 户 value 
Genotype Genotype 
TC (mmol/L) AA 7.67 1.52 21 0.953 AA 4.55 0.43 101 0.072 
GG 7.63 1.11 35 GG 4.65 0.30 11 
GA 7.60 1.12 58 GA 4.38 0.54 59 
TG(mmol/L)# AA 3.84 2.06 21 0.010* AA 0.91 0.38 101 0.699 
GG 5.35 3.34 35 GG 0.91 0.43 11 
GA 3.65 1.89 58 GA 0.92 0.37 59 
HDL-C 
AA 1.14 0.26 21 0.961 AA 1 4 9 0.32 101 0.079 
(mmol/L) 
GG 1.14 0.33 35 GG 1.46 0.33 11 
GA 1.12 0.26 58 GA 1.42 0.38 59 
LDL-C 
AA 5.17 1.58 18 0.601 AA 2.66 0.48 101 0.262 
(mmol/L) 
GG 5.08 1.47 21 GG 2.81 0.41 11 
GA 5.16 1.15 46 GA 2.54 0.57 59 
Total 85 Total 171 
FBG (mmol/L) AA 5.60 0.64 21 0.145 AA 4.98 0.58 101 0.716 
GG 5.46 0.73 35 GG 5.10 0.40 11 
GA 5.27 0.76 58 GA 4.96 0.44 59 
SBP (mmHg) AA 141.62 22.62 21 0.559 AA 116.24 12.63 101 0.531 
GG 142.70 16.54 35 GG 116.64 12.74 11 
GA 138.08 19.56 58 GA 113.14 11.72 59 
DBP (mmHg) AA 82.03 10.49 2 � 0.712 AA 68.61 9.31 101 0.652 
GG 81.13 12.02 35 GG 66.12 11.20 11 
GA 79.49 13.66 58 GA 67.75 8.35 59 
p values were calculated by ANCOVA adjusted for age, gender and BMI. 
*尸 < 0.05, # The TG levels of CH cases were log-transformed. 
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Table 12. Parameter analysis of FCH cases and controls according to different 
rs6589567 (APOA4-A5) genotypes 
CH cases Controls 
Parameters (n=l 15) Mean SD N P value (n=174) Mean SD N P value 
Genotype Genotype 
TC (mmol/L) AA 7.57 1.24 47 0.977 AA 4.53 0.45 118 0.334 
AG 7.66 丨 .�9 52 AG 4.41 0.53 47 
GG 7.55 I J O 16 GG 4.62 0.32 9 
TG (mmol/L) AA 4.26 2.59 47 0.898 AA 0.92 0.39 118 0.802 
AG 4.07 2.23 52 AG 0.90 0.33 47 
GG 4,68 3.42 16 GG 0.88 0.48 9 
HDL-C 
AA 1.11 0.25 47 0.270 AA 1.48 0.34 118 0.048* 
(mmol/L) 
AG l . n 0.27 52 AG 1.43 0.38 47 
GG 1.25 0.37 丨 6 GG 1.52 0.32 9 
LDL-C 
AA 5.18 1.37 35 0.665 AA 2.63 0.49 118 0.651 
(mmol/L) 
AG 5.18 丨.25 38 AG 2.57 0.57 47 
GG 4.80 丨.43 13 GG 2.74 0.42 9 
Total 86 Total 174 
FBG (mmol/L) AA 5.37 0.84 47 0.940 AA 4.99 0.56 118 0.881 
AG 5.43 0.66 52 AG 4.95 0.46 47 
GG 5.34 0.66 丨 6 GG 5.08 0.33 9 
SBP (mmHg) AA 138.78 19.81 47 0.727 AA 115.92 12.53 118 0.418 
AG � 4 ] . 5 6 19.28 52 AG 113.26 11.82 47 
GG 139.02 17.74 16 GG 118.56 12.46 9 
DBP (mmHg) AA 78.90 10.81 47 0.370 AA 68.26 9.50 118 0.958 
AG 82.01 13.44 52 AG 68.04 8.33 47 
GG 80.38 14.31 16 GG 69.15 9.62 9 J 
P values were calculated by ANCOVA adjusted for age, gender and BMI. 
*户 < 0 . 0 5 
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3.4.2.4 Haplotype analysis 
According to the default setting of the Haploview, three haplotype blocks were 
found. The first haplotype block consisted of two AP0C3 SNPs (rs452Q, rs5128) in 
strong LD (Table 31). The haplotypes carrying the minor alleles of rs4520 or rs5128 
were significantly associated with CH (户二0.0021, P=0.0024 respectively) (Table 31). 
The second haplotype block consisted of two APOA4-A5 SNPs frs6589567, 
rs6589568) (Table 32). The haplotype carrying the minor alleles of both SNPs was 
significantly associated with CH (户<0.001). The third haplotype block consisted of 
three APOAS SNPs frs2266788, rs65182K rs662799) (Table 33). Two haplotypes 
carrying the minor alleles of rs651821 and rs662799 were significantly associated 
with CH (P<0.001). 
Table 31. CH case-control association test of the haplotypes in AP0C3 
CH cases/Control CH cases /Control 
Haplotypes Chi square 尸 vaule 
counts ratios 
rs4520 rs5128 
1 1 77.2 117.9 0.336 0.335 0.0 0.9827 
2 1 63.3 140.7 0.275 0.400 9.45 0.0021* 
1 2 88.3 93.1 0.384 0.265 9.211 0.0024* 
P values were calculated by the Chi-square test. 
* P values were lower than the significance level adjusted with the Bonferroni's correction (P < 
0.017). Major alleles of each SNP are represented as 1 and minor alleles are represented as 2. 
The LD of the SNPs is L 0 D ^ 2 and D’=l. 
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Table 32. CH case-control association test of the haplotypes in APOA4-A5 
CH case/Control CH case /Control 
Haplotypes Chi square P vaule 
counts ratios 
rs6589567 rs6589568 
1 ] 139.0 254.9 0.604 0.724 9.118 0.0025* 
2 2 84.0 78.9 0.365 0.224 13.756 <0.001* 
1 2 7.0 18.3 0.030 0.052 1.538 0.2149 
P values were calculated by the Chi-square test. 
* P values were lower than the significance level adjusted with the Bonferroni's correction (P < 
0.017). Major alleles of each SNP are represented as 1 and minor alleles are represented as 2. 
The LD of the SNPs is L 0 D ^ 2 and D'=l. 
Table 33. CH case-control association test of the haplotypes in A P 0 A 5 
CH case/Control CH case /Control 
Haplotypes Chi square P vaule 
counts ratios 
rs2266788 rs651821 rs662799 
1 � I 101.0 268.1 0.439 0.762 62.408 <0.001* 
2 2 2 84.0 66.0 0.365 0.187 22.966 <0.001* 
1 2 2 45.0 16.9 0.196 0.048 31.972 <0.001* 
P values were calculated by the Chi-square test. 
*P values were lower than the significance level adjusted with the Bonferroni's correction {P < 0.017). 
Major alleles of each SNP are represented as 1 and minor alleles are represented as 2. 
The LD of the SNPs is L 0 D ^ 2 and D'=l . 
3.5 USFl gene 
3.5.1 FCH cases versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency between FCH cases and controls (Table 34). To 
avoid the counts expected by the Chi-square test in any cells of i.s3737787 and 
rs2774276 less than five, their minor allele homozygotes were combined with 
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herterozygotes. Genotypic distribution and allelic frequency of both SNPs were not 
significantly different between FCH cases and controls (P>0.05) (Table 34). The 
minor allele frequency of rs3737787 in Chinese FCH patients (0.12) was 
significantly lower than these in Caucasians (0.34) and Mexican FCH patients (0.22) 
(Pajukanta, Lilja et al. 2004; Huertas-Vazquez, Aguilar-Salinas et al. 2005). The 
SNPs in USFl were not selected to do any further analysis. 
3.5.2 CH cases versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency between CH cases and controls (Table 35). 
Genotypic distribution and allelic frequency of rs3737787 and rs2774276 were not 
significantly different between CH cases and controls (P>0.05) (Table 35). The SNPs 
were not selected to do any further analysis. 
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Table 34. Comparisons of genotypic distribution and allelic frequency of the SNPs in 
USFl between FCH cases and controls 
SNP Genotype Controls FCH cases P value 
rs3737787 (USFl) CC 1 12 (65.1) 42 (77.8) 
CT/丁丁 60(34.9) 12 (22.2) 0.081 
Total 172 54 
C/T allele 












Aguilar-Salinas et al. 
2005) 
rs2774276 (USFl) GG 122 (69.3) 44 (78.6) 
GC/CC 54 (30.7) 12 (21.4) 0.181 
Total 176 56 
G/C allele 
0.832/0.168 0.884/0.116 0.189 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
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Table 35. Comparisons of genotypic distribution and allelic frequency of the SNPs in 
USFl between CH cases and controls 
SNP Genotype Controls CH cases P value 
rs3737787 (USFl) CC 112 (65.1) 84 (73.7) 
CT/TT 60 (34.9) 30 (26.3) 0.127 
Total 172 114 
C/T allele 
0.808/0.192 0.860/0.140 0.109 
frequencies 
rs2774276 (USFl) GG 122 (69.3) 86 (75.4) 
GC/CC 54 (30.7) 28 (24.6) 0.258 
Total 176 114 
G/C allele …力 
. 0.832/0.] 68 0.864/0.136 0.304 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
3.6 LPL gene 
3.6.1 FCH versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of S447X between FCH cases and controls (Table 
36). The genotypic distribution and allelic frequency were not significantly different 
between FCH cases and controls (P>0.05) (Table 36). In Caucasians，the number of 
minor allele carriers of S447X in atherogenic patients was significantly lower than 
this in controls (18% vs 32%) (Table 38) (Morabia, Cayanis et al. 2003). The number 
of minor allele carriers of S447X in Chinese was lower than this in Caucasians (22% 
vs 32%). The SNP was not selected to do any further analysis. 
87 
3.6.2 CH versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of S447X between CH cases and controls (Table 
37). The genotypic distribution and allelic frequency were not significantly different 
between CH cases and controls (P>0.05) (Table 37). The SNP was not selected to do 
any further analysis. 
Table 36. Comparisons of genotypic distribution and allelic frequency of LPL S447X 
between FCH cases and controls 
SNP Genotype Controls FCH cases P value 
LPL S447X CC 137 (78.3) 46 (82.1) 
CG/GG 38 (21.7) 10 (17.9) 0.536 
Total 175 56 
C/G allele 
^ . 0.886/0.114 0.911/0.089 0.459 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
Table 37. Comparisons of genotypic distribution and allelic frequency of LPLS447X 
between CH cases and controls 
SNP Genotype Controls CH cases P value 
LPL S447X CC 137 (78.3) 96 (84.2) 
CG/GG 38(21.7) 18(15.8) 0.213 
Total 175 114 
C/G allele 
^ . 0.886/0.114 0.921/0.079 0.167 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
8 8 
Table 38. Comparisons of genotypic distribution of LPL S447X between atherogenic 
cases and controls in Caucasians (P37) (Morabia, Cayanis et al. 2003) 
SNP Genotype Controls atherogenic cases 
LPL S447X CC 68% 82% 
CG/GG 32% 18% 
3.7 PPARy gene 
3.7.1 FCH cases versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of 161 O T and - 6 8 1 0 G between FCH cases and 
controls (Table 39). The genotypic distribution and allelic frequency were not 
significantly different between FCH cases and controls (尸〉0.05) (Table 39). The 
SNPs were not selected to do any further analysis. 
3.7.2 CH cases versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of 161 C>T between CH cases and controls (Table 
40). The genotypic distribution and allelic frequency were not significantly different 
between CH cases and controls (/'>0.05) (Table 40). The SNP was not selected to do 
any further analysis. 
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Table 39. Comparisons of genotypic distribution and allelic frequency of the SNPs in 
P P A R y between FCH cases and controls 
SNP Genotype Controls FCH cases P value 
PPARy 
CC 89 (50.9) 29 (51.8) 
161 O T 
CT/TT 86 (49.1) 27 (48.2) 0.904 
Total 175 56 
C/T allele 
0.726/0.274 0.696/0.304 0.549 
frequencies 
PPARy 
CC 70 (40.5) 21 (37.5) 
- 6 8 1 0 G 
CG 84 (48.6) 24 (42.9) 
GG 19(11.0) 11(19.6) 0.246 
Total 173 56 
C/G allele … � 
0.647/0.353 0.589/0.41 1 0.267 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
Table 40. Comparisons of genotypic distribution and allelic frequency of the SNPs in 
PPARy between CH cases and controls 
SNP Genotype Controls CH cases P value 
PPARy 
� CC 89 (50.9) 57 (49.6) 
161 O T _； ； 
CT 76 (43.4) 45 (39.1) 
TT 10(5.7) 13(11.3) 0.216 
Total 175 115 
C/T allele 
0.726/0.274 0.691/0.309 0.371 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
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3.8 A D D l gene 
3.8.1 FCH cases versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of rs4961 between FCH cases and controls (Table 
41). The genotypic distribution and allelic frequency were not significantly different 
between FCH cases and controls (P>0.05) (Table 41). The SNP was not selected to 
do any further analysis. 
3.8.2 CH cases versus controls 
Pearson's Chi-square independence test was used to compare the genotypic 
distribution and allelic frequency of rs4961 between CH cases and controls (Table 
42). The genotypic distribution and allelic frequency were not significantly different 
between CH cases and controls (?>0.05) (Table 42). The SNP was not selected to do 
any further analysis. 
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Table 41. Comparisons of genotypic distribution and allelic frequency of ADDl 
rs4961 between FCH cases and controls 
SNP Genotype Controls FCH cases P value 
rs4961 GG 61 (35.3) 14 (25.0) 
GT 80 (46.2) 34 (60.7) 
TT 32(18.5) 8(14.3) 0.168 
Total 173 56 
G/T allele ‘ 
0.584/0.416 0.554/0.446 0.573 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
Table 42. Comparisons of genotypic distribution and allelic frequency of ADDl 
rs4961 between CH cases and controls 
SNP Genotype Controls FCH cases P value 
rs4961 GG 61 (35.3) 34 (29.6) 
GT 80 (46.2) 64 (55.7) 
TT 32 (18.5) 17 (14.8) 0.292 
Total 173 115 
G/T allele …力 
0.584/0.416 0.574/0.426 0.814 
frequencies 
P values were calculated by the Chi-square test. 
The numbers in ( ) represent the percentages. 
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Chapter four Discussion 
4.1 Comparisons of the findings with these of other studies 
4.1.1 APOA1/C3/A4/A5 gene cluster 
4.1.1.1 APOAl 
In a previous study, the minor allele of rs5070 was found to be associated with 
FCH, elevated TG levels and apoC3 levels in Caucasians (Groenendijk, Cantor et al. 
2001). In this study, the results have shown that there was no association between the 
SNP and FCH in Chinese. 
According to the data of the HapMap, the minor allele frequencies of the same 
SNP can be different among different ethnic groups i.e. blacks (Nigeria), Caucasians 
(USA) and Asians (China and Japan) (The international HapMap Consortium 2005). 
Wright's Fst is used to measure the fraction of total genetic variation due to 
between-population differences. Their data has suggested that the level of 
differentiation is the lowest between Caucasians and Asians (FST =0.07)，but the 
highest between blacks and Asians (Fst = 0.12) (The international HapMap 
Consortium 2005). In case-control studies, the samples from different ethnic groups 
must be analyzed separately (population stratification) to avoid variations. As this 
study and the Groenendijk's study genotyped the samples from different ethnicity, 
this may cause the discrepant results. 
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Other FCH studies including Groenendijik's study required FCH probands' TC 
and/or TG levels must be above or equivalent to 90山 percentile adjusted for age and 
gender, (Pajukanta, Nuotio et al. 1998; Groenendijk, Cantor et al. 2001; Hopkins, 
Heiss et al. 2003; Eichenbaum-Voline, Olivier et al. 2004). A Dutch study used the 
apoB levels above 75山 percentile to define FCH cases (Aouizerat, Allayee et al. 
1999). In this study, the absolute values of TC and TG levels were used to define 
FCH and CH cases. FHTG or CAD patients instead of FCH patients were recruited 
as cases in some case-control studies. These differences in ascertainment criteria may 
cause the discrepant results. 
4.1.1.2 APOC3 
Groenendijk et al suggested that the minor allele of rs4520 was associated with 
FCH and elevated TG levels in Caucasians (Groenendijk, Cantor et al. 2001). 
Conti.ai.ily, our results have shown that its minor allele (C) was protective against 
FCH and CH in Chinese. The relative risks of developing FCH and CH for the 
rs4520 heterozygotes were significantly lower as compared with those of the major 
allele homozygotes (OR=0.4, 0.4 respectively). 
Mai. et al reported that the minor allele of rs5128 was associated with FCH in 
Caucasians (Mar, Pajukanta et al. 2004). In this study, its minor allele (G) was 
associated with CH (P<0.05), but not with FCH in Chinese. The odds ratio of the 
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minor allele homozygotes (GG) compared with the reference genotype (CC) was 3.8 
(F=0.003). FCH sample size (n = 56) of this study was relatively small compared 
with the CH sample size (n = 115). This may explain why the SNP was associated 
with CH only. 
Olivieri and colleagues found that the minor allele carriers of rs2854116 were 
associated with an increased risk of CAD (OR=2.18 after adjustment) and increased 
TG levels in Caucasian CAD patients (Olivieri, Stranieri et al. 2002). The present 
study has found that its minor allele (C) was associated with CH (F<0.05), but not 
with FCH in Chinese. The odds ratio of the minor allele homozygotes (CC) 
compared with the reference genotype (TT) was 3.0 (P =0.003). 
The frequency of the haplotype carrying the minor alleles of rs4520 and rs5128 
was significantly higher in Caucasian FCH probands as compared with spouses 
CP<0.001) (Groenendijk, Cantor et al. 2001). In the present study, the haplotype 
consisting of the minor allele of rs4520 was found to protect against FCH and CH 
(P=0.018, P=0.0021 respectively). However, the frequency of the haplotype carrying 
the minor allele of rs5128 was significantly higher in CH patients as compared with 
controls (户二0.0024). The discrepant results may be attributed to the different 
ethnicity of the study samples. 
Apolipoprotein C3 is a non-competitive inhibitor of the LPL mediated 
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triglyceride hydrolysis that reduces the capacity to hydrolyze triglyceride rich 
lipoproteins (Wang, McConathy et al. 1985; Ginsberg, Le et al. 1986). 
Overexpression of human AP0C3 in transgenic mice was reported to elevate TG 
levels. AP0C3 SNPs such as rs5128 may overexpress AP0C3, so apoC3 and lipid 
levels are elevated. This mechanism may contribute to increase the CH susceptibility 
in Chinese. 
4.1.1.3 APOA4 
The minor allele of rs675 was suggested to have a protective role on the 
prevalence of FCH in Caucasians (尸=0.01) (Mar, Pajukanta et al. 2004). The minor 
allele carriers of G360H were also associated marginally with lower TC and TG 
levels ill Caucasians (Fisher, Burke et al. 1999). Our results have shown that both 
SNPs have no minor alleles in Chinese. 
4.1.1.4 APOA4-A5 
Three SNPs (rs6589567 , rs6589568, rsl729410) in APOA4-A5 were selected 
from the Hapmap for novel findings. To my knowledge, the associations of these 
SNPs with FCH or CH were not reported in the past. Exact functions of the SNPs in 
the APOA4-A5 intragenic region have not been defined yet. Our results have proved 
that the minor allele (A) of rs6589567 was associated with both FCH and CH 
(P<0.05). The odds ratios of its minor allele carriers compared with the reference 
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genotype (CC) for developing FCH and CH were 2.2 (P=0.016) and 3.5 (?=0.007) 
respectively. The minor allele (G) of rs6589568 was associated with both FCH and 
CH (户<0.05). Its minor allele carriers had significantly higher relative risk for 
developing FCH (OR=3.9, ？ = 0 . 0 0 6 ) and CH (OR=3.5, P=0.005) compared with the 
reference genotype (AA). The minor allele carriers of rs 1729410 were found to be 
associated with the lower relative risk of CH in Chinese (OR=0.2，P =0.005). 
A novel haplotype block consisting of the minor alleles of rs6589567 and 
rs6589568 was significantly associated with FCH (P二0.003) and CH (P=0.0002). 
The haplotype carrying the minor allele of rs6589568 only was not associated with 
FCH (P=0.524) and CH (?=0.2149). This indicates that rs6589567 of the haplotype 
may have a more important role to develop FCH and CH susceptibility. It is possible 
to use the APOA4-A5 SNPs as the prognostic indicators for FCH and CH 
susceptibility in Chinese. 
4.1.1.5 APOA5 
The minor allele of rs651821 was suggested to be associated with elevated TG 
levels and decreased HDL-C levels in general Singaporean Chinese (Lai, Tai et al. 
2003), and HTG (OR=3.23,尸<0.001) in Caucasians (Wright, Young et al. 2005). It is 
a noncoding, but potentially functional polymorphism in the start codon identified by 
Pemiacchio et al (Pennacchio, Olivier et al. 2001). They hypothesized that a less 
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efficient start codon due to the SNP would result in a decreased rate of apoA5 
synthesis and elevated TG levels (Pennacchio, Olivier et al. 2002). This study has 
shown that its minor allele (C) was strongly associated with both FCH (?<0.001) and 
CH (P< 0.001) in Chinese. The relative risk of its minor allele homozygotes (CC) for 
developing FCH (OR=24.4, ？<0.001) and CH (OR=17.0，P<0.001) were 
significantly higher than that of the reference genotype (TT). Its minor allele earners 
were marginally associated with higher TG levels in CH cases {P < 0.05). 
Previous studies have suggested that the minor allele of rs662799 was associated 
with elevated TG levels (Aouizerat, Kulkarni et al. 2003; Baum, Tomlinson et al. 
2003; Lai, Tai et al. 2003; Bi, Yan et al. 2004)，increased CAD risk (0R=1.8) (Bi, 
Yan et al. 2004) and CH (?=0.0002) (Aouizerat, Kulkarni et al. 2003) in Chinese. In 
Caucasians, Ribalta et al found its minor allele was associated with FCH probands 
(OR=3.25) (Ribalta, Figuera et al. 2002), but another study found no such association 
with FCH (Mar, Pajukanta et al. 2004). The present study has confirmed that its 
minor allele (G) was strongly associated with FCH (尸<0.001) and CH (户<0.001) in 
Chinese. The relative risk of the minor allele homozygotes (GG) for developing FCH 
(OR=24.6,尸<0.001) and CH (OR=16.841, PO.OOl) were significantly higher than 
that of the reference genotype (AA). Its minor allele carriers were marginally 
associated with higher TG levels in CH cases {P<0.05). 
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A previous study reported that rs2075291 was associated with the increased 
risk of developing HTG (OR=11.73, ？ < 0 . 0 0 0 1 ) and CAD (OR=2.089，户=0.017) in 
Chinese (Tang, Sun et al. 2005). The SNP is a coding sequence variant thai can result 
in the substitution of cysteine for glycine at residue 185 (G185C) in AP0A5. Our 
results have proved that its minor allele (A) was strongly associated with FCH in 
Hong Kong Chinese (?<0.001). Its minor allele carriers had a significant higher 
relative risk of FCH (OR=4.4, P<0.001) compared with the reference genotype (CC). 
Its minor allele carriers were also found to be associated with lower HDL-C levels in 
FCH cases marginally (户<0.05). 
Two previous studies found that rs2266788 was significantly associated with 
elevated TG and decreased HDL levels in Chinese (Kao, Wen et al. 2003; Lai, Tai et 
al. 2003). The results of this study have suggested that its minor allele (G) was 
associated with both FCH and CH in Chinese (尸<0.001). The relative risk of minor 
allele carriers for developing FCH (OR=6.2, P<0.001) and CH (OR=5.3, P=0.001) 
were significantly higher than that of the reference genotype (AA). Its minor allele 
carriers were associated with lower HDL-C levels in controls marginally (?<0.05). 
Several studies have proved that AP0A5 haplotypes were associated with 
elevated TG levels in different ethnic groups. Haplotype APOA5*2 defined by the 
minor allele of rs662799 was confirmed to be associated with elevated TG levels in 
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Caucasians (Pennacchio, Olivier et al. 2001; Pennacchio, Olivier et al. 2002; Talmud, 
Hawe et al. 2002). Lai et al have shown that two AP0A5 haplotypes carrying the 
minor alleles of rs651821 and rs662799 had major effects on elevated TG levels in 
Singaporean Chinese (Lai, Tai et al. 2003). This study has confirmed that two 
AP0A5 haplotypes consisting of the minor alleles of rs651821 and rs662799 were 
significantly associated with FCH (PO.OOl) and CH (PO.OOl) in Chinese. Our 
results suggest the possible use of AP0A5 SNPs as prognostic indicators for FCH 
and CH susceptibility in Chinese. 
The specific role of apoA5 in plasma lipid transport has not been defined yet. 
Two previous animal studies have demonstrated that the AP0A5 transgenic mice 
(AP0A5 overexpressers) displayed a decrease in TG levels (66%-70%) (Pennacchio, 
Olivier et al. 2001; van der Vliet，Schaap et al. 2002). One of the studies has also 
indicated that a sharp elevation of apoA5 levels (20-fold) might cause a 40% 
reduction in TC levels in the transgenic mice (van der Vliet, Schaap et al. 2002). In 
contrast, the AP0A5 knockout mice were observed to have 4-fold higher TG levels 
(Pennacchio, Olivier et al. 2001). Functional studies about the apoA5 have suggested 
that they can trigger the triglyceride lowering activity by retarding triglyceride-rich 
particle assembly and/or increasing LPL activity (Weinberg, Cook et al. 2003; 
Fruchart-Najib, Baiige et al. 2004; Schaap, Patrick et al. 2004). Animal studies have 
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suggested that plasma apoA5 levels may correlate negatively with plasma lipid levels 
in humans. We may postulate from our results that rs651821 and rs662799 in AP0A5 
may impair AP0A5 transcription and/or translation. One possibility is that rs662799 
in the promoter region of AP0A5 may slow down the signal initiation of AP0A5 
mRNA transcription. Another possibility is that rs651821 (-3 A>G) in the start 
Condon (consensus Kozak sequence) of AP0A5 changes the major allele A to the 
minor allele G at -3bp. The less efficient start codon may result in a decrease rate of 
AP0A5 mRNA transcription (Pennacchio，Olivier et al. 2002). Both cases can 
decrease the rate of apoA5 synthesis and thereby elevate TC and/or TG levels in 
Chinese FCH and CH patients. However, some recent studies have observed that 
apoA5 levels were positively correlated with TG levels in humans (Henneman, 
Schaap et al. 2006; Schaap, Nierman et al. 2006; Vaessen，Schaap et al. 2006). This 
indicates that the correlation of apoA5 and lipid levels may not be as straightforward 
as previously anticipated. More human studies are needed to assess the correlation of 
apoA5 and lipid levels. 
4.1.2 USFl 
In previous studies, two USFl SNPs (rs3737787, rs2073658) and their combined 
haplotype were found to be associated with FCH in Caucasians and Mexicans 
(Pajukanta, Lilja et al. 2004; Coon, Xin et al. 2005; Huertas-Vazquez, 
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Aguilar-Salinas et al. 2005). In this study, the genotyping results of rs2073658 were 
invalid due to the low call rate of the MassARRAY system. Another SNP rs3737787 
was not associated with FCH in Chinese marginally (户=0.08). The small FCH 
sample size (n=56) may lower the statistical power of the Chi-square test. The 
discrepant results may also be attributed to the different ethnicity of the study 
samples and differences in ascertainment criteria. 
4.1.3 LPL 
In the Framingham Offspring study, the minor allele of S447X was reported to 
protect against high TG levels, low HDL levels and premature CAD in Caucasians 
(OR=0.43,户=0.04) (Gagne, Larson et al. 1999). Morabia et al showed that the allele 
of the SNP could reduce the atherogenic OR in Caucasians (adjusted OR=0.39, 95% 
CI) (Morabia, Cayanis et al. 2003). In this study, S447X was not associated with 
FCH or CH in Chinese. Patients with different disorders and ethnicity may result in 
the discrepancy. 
4.1.4 PPARy 
Wang et al have suggested that the minor allele carriers of 161 C>T had 
significantly reduced CAD risk in Caucasians (Wang, Oosterhof et al. 1999). Another 
previous study reported that the minor allele of -681 C>G was associated with 
increased TC, LDL and apoB levels in a French population (Meirhaeghe, Fajas et al. 
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2003). Our results have shown that both SNPs were not associated with FCH or CH 
ill Chinese. The patients with different disorders and ethnicity may explain the 
discrepancy. 
4.1.5 ADDl 
Beeks et al reported that rs4961 was associated with FCH in Caucasians (Beeks， 
Janssen et al. 2001). Our results have suggested that the SNP was not associated with 
FCH or CH in Chinese. The different ethnicity and differences in ascertainment 
criteria may cause the discrepant results. 
4.2 Conclusions 
One SNP (rs452Q) in AP0C3, two SNPs (rs6589567, rs6589568) in APOA4-A5 
and four SNPs (rs651821, rs662799, rs207529K rs2266788) in AP0A5 and were 
found to be associated with FCH in Chinese. One haplotype in AP0C3, one novel 
haplotype in APOA4-A5 and two haplotypes in AP0A5 were also confirmed to be 
associated significantly with FCH in Chinese. Three AP0C3 SNPs (rs4520, rs5128, 
rs2854116), three APOA4-A5 SNPs (rs6589567, rs6589568. rs 1729410) and three 
AP0A5 SNPs (rs651821, rs662799. rs2266788) were associated with CH in Chinese. 
Two haplotypes in AP0C3, one novel haplotype in APOA4-A5 and two haplotypes 
in AP0A5 were also confirmed to be associated significantly with CH in Chinese. 
All these results implicate the possible use of the SNPs in the APOAl/C3/A4/A5 
103 
gene cluster as the prognostic indicators for FCH or CH susceptibility in Chinese. No 
SNPs in APOAl，AP0A4, USFl，LPL, PPARy or ADDl were found to be associated 
with FCH or CH. 
4.3 Implications for future research 
In this study, Bonferroni's correction was used to adjust the significance tests to 
avoid Type I errors (false positive results). The small sample sizes of the FCH (n=56) 
and CH (n=115) groups might cause Type II errors (false negative results). More 
studies with larger sample sizes are needed to further confirm the genetic 
associations through replication in Chinese. This study has suggested AP0A5 as the 
prime candidate in the APOAl/C3/A4/A5 gene cluster for increasing susceptibility to 
FCH and CH in Chinese. It will be more evident to study the correlation of apoA5 
and lipid levels by comparing the apoAS levels of FCH or CH patients with these of 
normal controls. More functional studies are also needed to understand the specific 
role of apoA5 in lipoprotein metabolism better. Apolipoprotein A5 is mainly present 
on HDL particles. Some studies have suggested that apoA5 may increase LPL 
activity. Two enzymes, CETP and LCAT, are also involved in the reverse cholesterol 
transport to liver by HDL particles. We may study how apoA5 affects the activities of 
these two enzymes and reverse cholesterol transport. In future, APOAS modulation 
can be a potential strategy lo reduce FCH, CH and CAD susceptibility. 
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